DEVELOPMENT OF MOUSE MODELS OF ORAL SQUAMOUS CELL CARCINOMA (OSCC) METASTASIS FOR THE EVALUATION OF EMERGING ANTI-METASTATIC NANOMEDICINE DRUGS by S. Marcazzan
UNIVERSITA´ DEGLI STUDI DI MILANO
Ph.D. IN ORAL SCIENCES
XXXI◦ CYCLE
DEPARTMENT OF BIOMEDICAL, SURGICAL AND DENTAL SCIENCES
Ph.D. dissertation
DEVELOPMENT OF MOUSE MODELS OF ORAL
SQUAMOUS CELL CARCINOMA (OSCC) METASTASIS
FOR THE EVALUATION OF EMERGING
ANTI-METASTATIC NANOMEDICINE DRUGS
MED/28
Ph.D. Candidate:
Sabrina Marcazzan
Matricola R11206
:
Prof. Giovanni Lodi
Co-tutor:
Dr. Mauro Ferrari
Ph.D. Coordinator:
Prof. Massimo Del Fabbro
Academic Year 2017-2018
Contents
1 Introduction 3
1.1 Oral Squamous Cell Carcinoma . . . . . . . . . . . . . . . . . 3
1.1.1 Epidemiology, incidence, and risk factors . . . . . . . . 3
1.1.2 Clinical stages and current therapeutic approaches . . 4
1.1.3 Causes of death in patients affected by HNSCC . . . . 8
1.1.4 Animal models of OSCC metastasis . . . . . . . . . . 10
1.2 The advent of nanomedicine for cancer therapy . . . . . . . . 16
1.2.1 Generations of the nanomedicine platforms . . . . . . 17
1.2.2 Nanomedicine for HNSCC therapy . . . . . . . . . . . 20
1.3 Aim of the dissertation . . . . . . . . . . . . . . . . . . . . . . 25
2 Viability assay and pDox uptake in OSCC cells 27
2.1 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . 27
2.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
2.2.1 Viability assay for HSC-3 cells after treatment with
doxorubicin and pDox NPs . . . . . . . . . . . . . . . 29
2.2.2 Cellular uptake study of pDox NPs and free doxoru-
bicin in HSC-3 cells . . . . . . . . . . . . . . . . . . . 30
3 An orthotopic model of OSCC metastasis 35
3.1 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . 35
3.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
3.2.1 Generation of a stable HSC-3 cell line expressing GFP
and luciferase . . . . . . . . . . . . . . . . . . . . . . . 38
3.2.2 Mice survival . . . . . . . . . . . . . . . . . . . . . . . 38
3.2.3 Development of the primary tumor . . . . . . . . . . . 40
3.2.4 Presence of lung and lymph node metastases . . . . . 40
3.2.5 Necropsy and ex vivo IVIS of mice organs . . . . . . . 46
3.2.6 Histology and immunohistochemistry . . . . . . . . . . 49
4 Development of a model of OSCC lung metastasis 60
4.1 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . 60
4.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
1
CONTENTS 2
4.2.1 Isolation of HSC-3 GFP M1 cell line and cell sorting . 61
4.2.2 New model of lung metastasis with HSC-3 M1 GFP/Luc
cell line . . . . . . . . . . . . . . . . . . . . . . . . . . 62
5 Use of pDox on a new OSCC metastatic cell line 67
5.1 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . 67
5.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
5.2.1 Viability assay for HSC-3 GFP/Luc M1 cells after
treatment with doxorubicin and pDox NPs . . . . . . 68
5.2.2 Cellular uptake study of pDox NPs and free doxoru-
bicin in HSC-3 GFP/Luc M1 cells . . . . . . . . . . . 69
6 Discussion and Conclusion 72
6.1 pDox NPs were significantly less cytotoxic than free doxoru-
bicin on HSC-3 and HSC-3 M1 cells . . . . . . . . . . . . . . 72
6.2 The orthotopic model of OSCC metastasis reported a mod-
erate prevalence of lung metastases . . . . . . . . . . . . . . . 73
6.3 Male and female athymic nude mice presented a different
prevalence of lung metastases . . . . . . . . . . . . . . . . . . 75
6.4 Lung metastases displayed similarities with the metastases
reported in HNSCC patients . . . . . . . . . . . . . . . . . . . 75
6.5 Lung metastases in the IV model of HSC-3 M1 cells presented
a diffuse tumor cell infiltration . . . . . . . . . . . . . . . . . 76
6.6 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
Acknowledgments 78
Bibliography 79
Chapter 1
Introduction
1.1 Oral Squamous Cell Carcinoma
1.1.1 Epidemiology, incidence, and risk factors
Oral Squamous Cell Carcinoma (OSCC) is included in the large group of
Head and Neck Squamous Cell Carcinoma (HNSCC), which is the sixth most
frequent type of cancer worldwide[1]. In the oral cavity, SCC is diagnosed
in 95% of cases and it is 3-4% of all human cancers[2, 3]. Indeed, more
than 300’000 new cases of lip/oral cavity SCC (age-standardized to the
world population or ASR[W]: 4.0 x 100’000) were reported in 2012 with an
estimated mortality-ASR[W] of 2.7 per 100’000 worldwide[4].
In the US and in Europe, the most common tumor locations in the
oral cavity are the tongue and the floor of the mouth, while other loca-
tions such as the buccal mucosa, gingiva, and hard palate are reported less
frequently[4]. In the past decades, a higher incidence of oral cavity SCC was
reported in men than in women, due to the greater exposure to the main
risk factors. However, this trend has declined from 5:1 in the 60s to less
than 2:1 in 2002[3].
Tobacco and alcohol consumption are the most known major risk factors
for OSCC[3, 4]. The carcinogenic effect of tobacco is dose-dependent and
studies conducted in Europe and America have revealed a synergy between
tobacco and a heavy consumption of alcohol[4, 5]. In the Asian countries,
tobacco is commonly mixed with the betel quid, formed by slaked lime,
betel leaf, and areca nut, which is also a known carcinogen. The interaction
between tobacco, alcohol and betel quid chewing has proven to increase the
risk for oral cavity SCC[4].
Recently, the human papillomavirus (HPV) has been recognized as an
important emergent risk factor for HNSCC, particularly for oropharyngeal
3
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SCC. In the oral cavity SCC, a contribution of HPV is estimated only in 7-
16% of cases, compared to 40% -60% of oropharyngeal SCC cases reported
worldwide[3, 4]. In addition, an interaction between HPV, tobacco, and
alcohol is currently under investigation[4]. Other factors that may contribute
to the emerging of oral cavity and oropharyngeal SCC include a low socio-
economical status, the oral microbiome, dietary factors (e.g. vegetables
may have a protective effect), HIV infection or organ transplantation due
to immunosuppression, certain heritable conditions, and exposure to heavy
metals or solvents[3, 4, 5].
1.1.2 Clinical stages and current therapeutic approaches
Oral cancerogenesis is a complex multifactorial process. In the oral cav-
ity, common potentially malignant lesions include leukoplakia and erythro-
plakia. Leukoplakia is defined as ”a white patch or plaque that cannot be
characterized clinically or pathologically as any other disease” and its ma-
lignant potential is well known [4]. In addition, an uncommon variant of
leukoplakia (proliferative verrucous leukoplakia/PVL) has been reported,
especially in patients which do not present the common risk factors for oral
cavity SCC. PVL may progress to oral cavity SCC or a verrucous carci-
noma, a certain well-differentiated subtype of oral cavity SCC. Other risk
factors for verrucous carcinoma include tobacco chewing and dry snuff[4].
Erythroplakia is defined as ”a fiery red patch that cannot be characterized
clinically or pathologically as any other definable disease”[4]. In contrast
to leukoplakia, histological analysis of erythroplakias may show high-grade
dysplasia, carcinoma in situ, or invasive SCC[4].
Table 1.1 shows the current therapies adopted for each stage of oral cavity
SCC (TNM Clinical Classification or cTNM) . Despite efforts in improving
the therapeutic approach, the prognosis of patients with oral cavity SCC
remains poor, with a 5-year survival rate of around 50% worldwide. In the
US, the 5-year survival rate of OSCC is 63%. In addition, death rates did
not improve significantly between 2002 and 2012 [4, 6].
Traditionally, early-stage primary OSCC (I-II) has been treated with a
radical surgery, whose complete response (CR) has been reported in 60%-
80% of cases. CR is achieved when the histological examination reveals
negative surgical margins (surgical margin free of tumor) and two different
examinations separated by an interval > 4 weeks do not show evidence of
tumor [7, 8]. A large study on 200 patients with oral cavity or oropharyngeal
SCC reported an overall survival (OS) of 60% in the patients with negative
margins at 5 years, while 16% died free of SCC[7]. In contrast, patients
with close (tumor within 5 mm of margins) or involved margins (evidence
of tumor at the margins) had an OS of 36% and 11% respectively[7]. This
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Table 1.1: Standard treatments for oral cavity SCC[9, 113, 114]
Stage cTNM Classification Treatment
I T1 N0 M0 radical surgery of the primary
II T2 N0 M0 tumor with 1-2 cm margins ±
ipsilateral/bilateral neck dis-
section/sentinel lymph node
biopsy
III T3 N0 M0 surgical treatment + ipsilate-
T1 N1 M0 ral or bilateral neck dissection
T2 N1 M0 + chemoradiation or radiothe-
T3 N1 M0 rapy
IV a T4a N0 M0 surgery of the primary tumor
T4a N1 M0 + ipsilateral/bilateral neck
T1 N2 M0 dissection followed by con-
T2 N2 M0 current chemoradiotherapy;
T3 N2 M0 chemoradiotherapy followed
T4a N2 M0 by neck dissection (if surgery
IV b T4b Any N M0 was not an option);
Any T N3 M0 immunotherapy for metastatic
cancer if progression on or af-
ter chemotherapy
IV c Any T Any N M1 chemoradiotherapy only (if
surgery is not an option); im-
munotherapy for metastatic
cancer if progression on or af-
ter chemotherapy
result was mainly attributed to the aggressive behavior of the disease, which
also presents a higher risk for local (55% in patients with close margins) and
regional recurrence (22% in patients with close margins). In such cases, the
use of adjuvant radiotherapy has been effective in the local control of the
disease, but not in improving the long-term survival[7].
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Advanced-stage oral cavity SCC has been traditionally treated with surgery
and radiotherapy, despite substantial adverse effects may occur [3, 2]. The
addition of postoperative adjuvant chemotherapy to radiotherapy has im-
proved the OS by up to 16%. For instance, concomitant chemoradiother-
apy reported an improvement in OS of 10-22% compared with radiotherapy
alone in patients with unresectable tumors[3]. In contrast, the use of induc-
tion chemotherapy has not shown benefits in improving the OS compared
to locoregional treatment alone[3]. However, a reduction of locoregional
recurrence may be achieved in the oral cavity SCC patients undergoing in-
duction chemotherapy[3, 4]. Finally, the combination of radiotherapy and
chemotherapy may result in a substantial increase in toxicity per patient
treated[3].
Chemotherapy is the administration of anticancer or ”cytotoxic” drugs,
whose mechanism of action consists in altering the life cycle of cancer cells.
Since different types of chemotherapeutic agents target different stages of
the life cycle of tumor cells, it is common to combine two or three different
drugs into a chemotherapeutic regimen. In OSCC, the common standard
chemotherapeutic regimen for 20 years has been the combination of cis-
platin and 5-fluorouracil (5-FU)[3]. Indeed, an alkylating agent such as
cisplatin interferes with the cellular divisions, inducing a cross-linking of
DNA and activating cell apoptosis. 5-FU is classified in the antimetabo-
lites and inhibits the synthesis of thymidylate, an enzyme essential for DNA
replication[10, 87].
Other widely used chemotherapeutic agents include carboplatin, oxali-
platin (alkylating agents), methotrexate (antimetabolite), docetaxel, and
paclitaxel [3, 12, 13]. These last two agents are classified in the taxanes
and inhibit the replication of the tumor cells by altering the microtubule
function. They were added to chemotherapeutic regimens for OSCC treat-
ment in 2007 and their combination with cisplatin and 5-FU demonstrated
to be superior to cisplatin and 5-FU alone,[3, 14]. More in detail, a de-
crease in toxic deaths and an increase in OS (70.6 months vs 30.1 months)
were achieved combining docetaxel with cisplatin and 5-FU compared with
cisplatin and 5-FU alone[14].
The efficacy of chemotherapy in OSCC is currently reduced by the consis-
tent adverse effects and multi-drug resistance (MDR). For instance, cisplatin
may cause nephrotoxicity, neurotoxicity, gastrointestinal toxicity, hemato-
logical toxicity, and ototoxicity, while 5-FU has toxic effects on bone marrow-
[10, 87]. Other adverse effects of chemotherapy may consist in anemia, tired-
ness, nausea/ vomiting, diarrhea or constipation, hair loss, mucositis, and
susceptibility to infections. Adverse effects are the result of the non-specific
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distribution of chemotherapeutic agents within the body, which target the
normal cells in addition to the tumor ones[10, 15]. The type and the grade of
collateral events depend on the type of agent, the dosage used, the duration
of the treatment, and the patient [3, 10, 15].
Several mechanisms of MDR contribute to the collateral effects of chemothe-
rapy, resulting in an exposure of healthy cells to high levels of expelled
chemotherapeutic agent[13, 15]. The most known mechanism of MDR which
occurs also in OSCC is the overexpression of multi-drug transporters [e.g.
MDR1 or P-gp, ATP binding cassette (ABC)C1, ABCG2], which promote
the eﬄux of drugs from the tumor cells. As a consequence, the intracellular
concentration of the drug decreases along with the drug efficacy. Studies on
cell lines resistant to cisplatin and 5-FU and in recurrent OSCC have re-
ported an overexpression of ABCC1, P-gp, and ABCG2. In addition, P-gp
positive OSCC cells may become resistant to the taxanes and its expression
can be induced by chemotherapy (acquired resistance)[13]. In contrast, an
overexpression of MRP1 has been found in OSCC cell lines treated with cis-
platin, while the over expression of ABCG2 has been associated with cancer
stem cell properties and a MDR to cisplatin and 5-FU[13].
Other mechanisms of MDR reported in OSCC include the dysfunction of
apoptosis (e.g. up regulation of Bcl-2 and Bcl-xL), the enhancement of DNA
repair, which is crucial for platinum-based chemotherapy, epithelial mes-
enchymal transition (EMT), the dysregulation of miRNAs, and autophagy.
However, further investigation is necessary in order to elucidate the exact
molecular mechanisms of MDR in OSCC[13].
Recently, molecular-targeted agents are also being developed to enhance
the efficacy of the treatment for OSCC[6]. Indeed, these new agents have
the capability to target molecular changes highly specific to OSCC, reducing
the toxic effects on the normal cells. For instance, several monoclonal an-
tibodies (mAb) against the epidermal growth factor receptor (EGFR) such
as cetuximab, panitumumab, and nimotuzumab have been developed for
OSCC[6, 14]. Indeed, EGFR is overexpressed in 80%-90% of HNSCC and
its expression has been correlated with a poor outcome[2, 6].
Clinical studies using anti-EGFR mAb in combination with standard
therapies have reported an increase in the OS and locoregional control of
patients, most affected by oropharyngeal cancer, compared with standard
treatments alone[6]. In addition, a retrospective study reported a CR rate of
33.3% in patients with locally advanced or recurrent/metastatic OSCC[2].
However, the administration of cetuximab has been associated with severe
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collateral effects such as infusion reactions, skin toxicity, rash, neutropenia,
and interstitial pneumonia in rare cases[2, 6].
Other targeted therapies like bevacizumab and vandetanib (anti-VEGF
therapies), and immunotherapy have also been explored[6, 8, 13].
1.1.3 Causes of death in patients affected by HNSCC
Death caused by HNSCC has been reported in 29-64% of patients. In-
deed, several studies have shown that patients affected by HNSCC may
frequently die also from a cause other than HNSCC[16]. In these cases, the
onset of secondary carcinomas is considered the leading cause of death (27%-
54%)[16, 17]. In such cases, lung cancer and bronchus cancer are the most
common type of second cancer reported with a 50% prevalence followed by
esophageal (10%) and colorectal cancer (5%)[17, 18]. Cardiovascular disease
also exerts a significant impact on the patient’s survival: death from car-
diovascular diseases is reported in 21-28%. Other frequent causes of death
other than HNSCC include chronic obstructive pulmonary disease, pneumo-
nia, and influenza[17].
Among the OSCC-related deaths, the most frequent causes of death are
local recurrence and metastases[16, 19]. In a study, locoregional recur-
rence represented 80% of the OSCC-related deaths[16]. Recurrence occurred
mainly in the sublingual sulcus, tongue, and the floor of the mouth. In-
terestingly, distant metastases (DMs) were present in almost 41% of the
patients with locoregional recurrence, while DMs alone were attributed to
the remaining 20% of the OSCC-related deaths. Interestingly, the locore-
gional control rate of the disease reported was around 80% in patients with
stage T2-T4 resectable tumors without DMs (TNM classification 7th Edi-
tion) undergoing preoperative radiochemotherapy. After 5-6 weeks, radical
locoregional surgery was performed in all patients, including lymph node
resection according to N stage[16].
Another study reported an improvement of locoregional control in HNSCC
patients treated with the combination of chemotherapy and radiation com-
pared with radiation alone. However, the incidence of DMs was not signifi-
cantly different between the two groups (21% chemotherapy plus radiation
vs 25%radiation alone)[20]. In addition, more cases with DMs have recently
been diagnosed, due to the improvement achieved by the multimodality
treatment[21]. After the failure of platinum-containing chemotherapy, there
are currently few therapeutic options for patients with DMs and the use of
cetuximab is restricted by severe adverse effects that may often occur[2, 20].
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Regional and distant metastases in OSCC
Regional metastases in lymph nodes are a common finding in patients with
OSCC. Indeed 40% of OSCC may metastasize to the regional lymph nodes,
especially advanced stages of the disease[22]. In presence of lymph node
metastases, patients undergo a neck dissection, which is currently recom-
mended also for the management of clinical lymph-node negative (cN0) tu-
mors (see Table 1.1)[9] . Despite T1 and T2 tumors (TNM classification
7th Edition) have a low risk to develop lymph node metastases (10-30%
respectively), it has been demonstrated that occult lymph node metastases
may occur in T1 (6-25%) and T2 lesions (20-32%)[4, 22]. In order to detect
the occult metastases, sentinel lymph node biopsy is also performed and
may constitute an alternative to neck dissection in patients affected by T1
and T2 oral cavity SCC according to TNM classification 7th Edition[113].
In the oral cavity, the tongue is the most frequent site of OSCC which is
prone to invade the regional lymph node, compared with the floor of the
mouth[4, 23].
It is well known that the presence of lymph node metastases constitutes
an important prognostic indicator for OSCC and correlates with a poor
prognosis. Indeed, the 5-year survival rate of patients with lymph node
metastases is only 25-40% compared with 90% of those without lymph node
metastases. In the US, an increase of the 5-year survival rate was achieved
between 2005 and 2015 (from around 50% to 60%) in patients with invasion
of lymph node and\or surrounding tissues [24]. Size of the primary tumor,
site, T stage, grade, depth of invasion, biological tumor markers, perineural
invasion, and patient compliance are reported to affect the development of
lymph node metastases. However, the mechanisms of metastasis are still
poorly understood [22, 23, 25].
When single versus multiple lymph node metastases are detected outside
the sentinel node area, the patients have also a higher risk of DMs (41-
43%)[23]. In the case of DMs, the prognosis is poor and the control over
them remains low. In the US, the 5-year survival rate of patients with DMs
was around 30% in 2005 and increased by 35% in 2015. In addition, the
incidence of DMs increased from 10% of cases diagnosed in 2005 to 18% in
2015[23, 24].
DMs are found more frequently in oropharyngeal SCC cases than in oral
cavity SCC ones. Indeed, a recent study reported that 60% of DMs derived
from the pharynx SCC, followed by the tongue one (50-53%)[26]. Another
study also reported a metastasis rate of 6.6% and 4.1% from upper gingiva
SCC and tongue SCC respectively[26, 27]. This finding was also confirmed
by another study[27]. A larger study on 502 patients with oral cavity SCC
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reported DMs in 54 patients (10.8%) from 1 month to 76 months after radical
surgery[28]. More than half of the patients (29\54 53.7%) also presented
locoregional recurrence and their prognosis was better than those without
local recurrence. The lung was the most frequent site of DMs (44\54 81.5%),
followed by the bone (25\54 46.3%), mediastinum (10\54 18.5%), and liver
(9\54 16.6%). Less common locations were kidney (3\54), brain (2\54),
spleen (2\54), and adrenal gland (2\54)[28]. Other studies confirmed the
lung as the most frequent distant site of DMs in HNSCC patients[2, 26, 27].
Some studies reported also metastases in mediastinal, parapharyngeal lymph
nodes, heart and, peritoneum[2, 21, 26].
The median OS of patients with DMs is 3-8 months[2, 21, 28]. In par-
ticular, the presence of lung and bone metastases is significantly associated
with a poorer survival than patients without lung and bone metastases.
In a study by Takahashi et al.[28], the histological grade and the presence
of lymph node metastases were the most significant prognostic factors for
the development of lung and bone metastases, respectively. The presence
of bone metastases resulted in the lowest median OS (1.80-2.32 months),
which is also shorter than those of patients with bone metastases from other
cancers (e.g. breast and prostatic cancer)[21, 28]. For these reasons and for
the increasing incidence of DMs, further studies are needed to investigate
the basic mechanism of DMs in OSCC.
1.1.4 Animal models of OSCC metastasis
As reported in 1.1.3, it is necessary to fully understand the metastatic pro-
cess of OSCC, especially the development of DMs. In OSCC research, animal
models have contributed to the understanding of the molecular mechanism
of lymph node metastases, elucidating the role of VEGF-C and VEGF-D in
lymphangiogenesis. These factors have recently received clinical relevance[25].
However, reproducing metastases in animal models is difficult, due to
the recapitulation of all steps of the metastatic dissemination: tumor pro-
liferation, local invasion, intravasation, extravasation, colonization in the
metastatic site, and proliferation[29]. In addition, the interaction of the
cancer cells with the tumor microenvironment, tumor-associated immune
cells, and stromal cells may contribute to metastases[29, 30]. The animal
models used to resemble cancer metastases are Drosophila, zebrafish, mice,
rats and less frequently rabbits, companion pets, and monkeys. The most
used animal in cancer research has been the laboratory mouse, which has
been genetically modified over the years[29].
In cancer research, the most used mouse models consist in the transplan-
tation of murine cell lines into another mouse recipient of the same genetic
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background (syngeneic model) or in transplantation of human cell lines into
an immunodeficient mouse host (xenograft model). In such models, metas-
tases have been obtained by the direct injection of the tumor cells into the
systemic circulation (e.g. tumor cells injected into the tail vein to produce
lung metastases) or by the injection of tumor cells in the site of origin of
the primary tumor (orthotopic model). On one side, important drawbacks
of the first type of metastatic model are the lack of the primary tumor and
the reproduction only of the late phases of the metastatic dissemination.
On the other side, the orthotopic model requires a long period for the de-
velopment of metastases. Other mouse models frequently used to reproduce
metastases of certain types of cancers (breast, prostate, and lung cancer)
are the genetically engineered mice (GEM). These models have been devel-
oped by engineering mice to express (transgene) or not express (knockout)
a gene of interest. This has allowed researchers to humanize mice through
the replacement of murine genes with their human counterparts[29].
Several animal models of OSCC have been developed, but only a few of
them have shown the development of metastases, especially DMs[31, 32].
A list of the mouse models of OSCC metastasis is reported in Table 1.2,
with a specific focus on DMs. The xenograft models have the advantage of
using human cell lines to establish the tumor, but the lack of a complete
immune response does not permit to evaluate the role of immunity in the
metastatic process and in the response to treatment. In such cases, a syn-
geneic immunocompetent model is more realistic and appropriate[31]. In the
literature, both xenograft and syngeneic mouse models of OSCC metastasis
have been published. In such studies (Table 1.2), lymph node metastases
were present in almost all the cases and some of the models presented also
a high prevalence of lung metastases[32, 50, 52].
Regarding the transplantation of OSCC cells, several authors have re-
ported the inadequacy of the subcutaneous (SC) models of OSCC. Indeed,
they do not mimic the metastatic process observed in human OSCC and
the tumor microenvironment of their growth is different from the one of the
orthotopic site. In addition, SC models do not resemble the response to
treatments observed in clinical trials.[31, 32, 58]. In a study published by
Myers et al.[48], a greater tumorigenicity of OSCC cells was reported in the
orthotopic site than the SC one[48]. Indeed, most of the published mouse
models of OSCC metastasis are orthotopic and some of them developed DMs
also in other sites such as the liver and bone[32, 50].
There are also few articles which reported the tail vein injection of OSCC
cells[56, 92]. Indeed, important limitations of this model are the lack of
the primary tumor and the high number of cells required, whereas only few
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tumor cells are involved in the metastatic dissemination of OSCC[31, 55].
In such models, the lung metastasis rate is higher than some orthotopic
models, but they lack lymph node metastases compared with the orthotopic
ones.
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Finally, the use of GEM in OSCC research is rare and they do not metas-
tasize frequently. A 25% of lymph node metastases in the para-tracheo-
pharyngeal-esophageal regions was reported in L2D1+/p53+ mice, which
developed cancer in the anterior and posterior tongue, the cheek mucosa,
the upper, and lower esophagus. In contrast, chemically-induced OSCC
animal models such as the dimethyl-1,2, benzanthracene (DMBA)-induced
cheek pouch tumors in the hamster and the 4NQO-induced oral cavity SCC
in the rat have been frequently used. However, the tumor formation requires
several months and the metastasis rate is low[31].
In conclusion, the development of animal models of OSCC metastasis is
necessary not only to investigate the metastatic process of OSCC but also
to evaluate new emergent therapies, such as nanomedicine-based ones[59].
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1.2 The advent of nanomedicine for cancer thera-
py
In recent times, the field known as nanomedicine has emerged from the
union between nanotechnology, medicine, physics, mathematics, and biol-
ogy. Goals of this new field are to design new platforms to enhance the
efficacy and the specificity of the existing therapies and support the diagno-
sis of several diseases with few toxic effects. These results are being partially
achieved thanks to the development of nanoparticles (NPs)[60].
NPs are particles which exist on a nanometer scale (i.e., below 100 nm
in at least one dimension)[60, 111]. They have been applied not only as
anticancer drugs, but also as ultrasound contrast agents, vaccines, anesthet-
ics, fungal treatments, anemia, macular degeneration therapies, and imaging
tools. In addition, other applications such as gene therapies, therapies for
bacterial infections, inflammation (arthritis), and graft versus host disease
(GVHD) are currently under investigation[61]. Indeed, NPs are suitable
carriers of several compounds such as chemotherapeutic agents, anticancer
drugs, nucleic acids, contrast agents for imaging applications, and natural
compounds[5, 61, 62].
In oncology, NPs have achieved a great relevance and their application
includes not only the treatment of several types of cancer but also cancer
imaging and thermal ablation of tumors[61]. There are several advantages of
using NPs instead of the free drugs alone. Indeed, such systems may increase
the solubility and chemical stability of the drugs, protect the same drugs
from the degradation and the immune cells, and increase the circulation
time. As a consequence, the half-life of the compounds increases together
with the therapeutic effect. In addition, the specific accumulation of NPs in
tumors results in a further increase of the efficacy[60, 61, 62].
Therapeutic and diagnostic NPs are classified into two categories: inor-
ganic and organic particles. Inorganic particles consist of materials like gold,
silver, silica, iron oxide and they have been clinically approved for imaging
applications. In contrast, organic particles have been clinically approved
for cancer therapy and they are made of polymers or lipids (liposomes or
micelles)[61, 62]. Most of the NPs clinically approved for cancer treatment
are liposomes and are reported in Table 1.3.
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1.2.1 Generations of the nanomedicine platforms
First generation
Liposomes consist of a semisolid phospholipid layer and have been widely
used in cancer treatment due to their reduced toxicity and their tumor
specificity[63]. They are considered the first-generation nanomedicine drugs
due to their passive accumulation in the tumor. This is owed to the fact
that tumor vessels have larger endothelial fenestrations (between 100 nm
and 780 nm of size) than normal endothelium. This phenomenon is known
as the enhanced permeability and retention (EPR) effect and allows NPs
to extravasate and enter the tumor interstitial space[61, 62, 64]. All of the
NPs currently approved for cancer therapy belong to the first-generation
nanomedicine drugs[61, 62]. However, passive targeting alone has some lim-
itations. Indeed, it has been reported a heterogeneity of EPR within and
between tumor types due to tumor location, macrophage infiltration, and
site (primary vs metastatic). In addition, the treatment with NPs does not
always result in a significant increase of OS[64]. For these reasons, second-
generation nanomedicine drugs have been developed.
Second generation
The second-generation of NPs is characterized by the addition of components
for active targeting or by stimuli-responsive systems. In the preclinical set-
ting, actively targeted NPs have shown an enhanced tumor specificity and
drug retention in tumors thanks to the ligand-receptor binding[61, 62]. The
early clinical results of some of these systems are promising, but none of
these are clinically approved. In addition, the ligand used for active tar-
geting (e.g. monoclonal antibodies) may result in an increase of the NPs
uptake by the cells of the mononuclear phagocyte system (MPS), reducing
the concentration of NPs in the tumor and therefore the efficacy[15, 61, 62].
Stimuli-responsive systems are principally inorganic NPs. For instance,
gold NPs have the capability to convert the electromagnetic radiation from
a light source (external stimulus) into heath[65]. Other examples of stimuli-
responsive systems are those capable to release the compound in response to
changes in pH, reductive agents or temperature (internal stimulus), which
occur in the tumor microenvironment. Additionally, some of these systems
are currently being investigated in several clinical trials[61, 62].
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Table 1.3: Clinically approved nanomedicine systems for cancer therapy
Name Type Approved application Country
Doxil/Caelyx liposomal secondary treatment for ovarian EU,US
doxorubicin cancer, HIV-associated Kaposi′s
sarcoma, and multiple mieloma
Myocet liposomal primary treatment for metastatic EU
doxorubicin breast cancer
DaunoXome liposomal primary treatment for HIV US
doxorubicin associated Kaposi′s sarcoma
Marqibo liposomal tertiary treatment for ALL US
vincristine FAB type L1
MEPACT liposomal primary postoperative treatment EU
mifamurtide for osteosarcoma
Onivyde liposomal secondary treatment for US
MM-398 irinotecan metastatic pancreatic cancer
Abraxane albumin-particle primary treatment for metastatic EU, US
bound paclitaxel pancreatic cancer; secondary
treatment for metastatic
breast cancer; advanced NSCLC
if surgery or radiotherapy not
an option
Legend: ALL FAB type L1 = Philadelphia chromosome-negative acute lym-
phoblastic leukemia; NSCLC = non-small cell lung cancer.
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Third generation
The third-generation of NPs platforms has been developed to sequentially
overcome the biological barriers, which reduce the efficacy of the NPs sys-
tems injected intravenously. The first barrier is represented by the cells of
the MPS, which contribute to the non-specific accumulation of NPs in organs
such as liver and spleen. In the blood vessels, the fluid dynamics influences
the flow of the NPs and is therefore considered another important barrier.
Depending on the geometry of the NPs, their interaction with the endothe-
lium may decrease or increase (e.g. spheric vs discoidal geometry). In
addition, the intratumoral pressure can strongly decrease the extravasation
of NPs by the EPR effect. At the intracellular level, endosomal compart-
mentalization and MDR may limit the NPs-based drug delivery[15, 60, 66].
The third-generation nanomedicine platform multistage nanovector (MSV)
has shown advantages over the NPs of the previous generations, thanks to
the activation of several components in a sequential manner. It is charac-
terized by a discoidal first-stage mesoporous silicon particle (S1MP) in the
micrometer range carrying a second-stage NPs (S2NPs) embedded within
the nanopores[60, 67]. Following intravenous (IV) injection, this system is
able to protect the S2NPs from the cells of the MPS within the circulation,
adhere to tumor endothelium and release the S2NPs directly into the tumor
interstitial space[60, 68, 69]. Thanks to the geometry and the size of the
S1MPs, MSVs may accumulate preferentially in metastatic sites such as the
lungs, compared to other conventional NPs systems[66, 68, 69]. This pecu-
liarity results in an efficacy also against lung metastases, obtained in animal
models of different types of cancer. For instance, a down-regulation of ki67
and CD31 was obtained in an orthotopic mouse model of ovarian cancer
with the administration of MSVs with liposomes containing EphA2-specific
siRNA embedded within the nanopores. Similarly, lung metastases signif-
icantly decreased in mice bearing A375SM-Luc melanoma lung metastases
treated with MSVs loaded with liposomes containing siRNA and polymeric
NPs with docetaxel compared with the administration of the two types of
NPs alone[60, 68, 69].
Beyond the third generation
Moreover, a more elaborate NP system has been recently published by Xu
et al.[66]. The system includes an injectable NP Generator (iNPG) loaded
with a polymeric doxorubicin (pDox). The iNPG consists of a mesoporous
silicon particle packaged with doxorubicin binding to poly (L-glutamic acid)
through a ph-sensitive linkage (pDox). Once iNPG-pDox accumulates into
the site of interest due to innate tropism and adheres to the tumor endothe-
lium, pDox self-assembles into NPs in situ and enters tumor interstitial
CHAPTER 1. INTRODUCTION 20
space. Intratumorally, pDox is internalized by the tumor cells and dox-
orubicin is released in the perinuclear region, thanks to the cleaving of the
pH-sensitive linker, overcoming the MDR eﬄux pumps. The use of iNPG-
pDox resulted in an anti-metastatic efficacy and a significant increase of the
survival time (233 d) in an orthotopic mouse model of breast cancer lung
metastases compared with free doxorubicin (98 d) and Doxil (124 d)[66].
In conclusion, several NPs systems are emerging for cancer therapy and
they can be rationally designed to overcome sequential barriers and to target
specifically metastatic sites. For these reasons, they are promising systems
also for OSCC therapy. Some clinical and preclinical studies have been
published on the use of different NPs systems in OSCC[59].
1.2.2 Nanomedicine for HNSCC therapy
Clinical studies
The NP system Doxil/Caelix clinically approved for other types of cancer
has been also evaluated as adjuvant chemotherapy on patients with ad-
vanced and\or metastatic HNSCC[63, 70, 71, 72]. The phase 1 evaluation
in 24 patients with recurrent (21 patients) and metastatic HNSCC (3 pa-
tients) showed an overall response rate of 33% with few adverse effects (skin
toxicity, stomatitis, neutropenia). Oral cavity was the site of the primary
tumor in 10\24 patients[63]. In phase II clinical trial, Doxil was used as
induction chemotherapy prior radiotherapy in 20 patients with locally ad-
vanced unresectable HNSCC. In this study, no cardiotoxicity and no grade
3\4 hematological toxicity were reported. A partial response (PR) to Doxil
was also achieved in 20% of lymph node metastases. However, only four
patients were affected by oral cavity SCC[70]. In addition, a larger study
on 74 patients with locoregional recurrent and\or metastatic HNSCC did
not report any significant difference in survival and overall response rate
between patients treated with paclitaxel plus Doxil (36 patients) and those
treated with paclitaxel plus gemcitabine (38 patients)[72].
In another study, Faivre et al.[71] administrated Doxil to patients with
locoregional relapse of HNSCC in irradiated areas (17\26 patients) and/or
with DMs (12 patients). Most of the patients included presented oropha-
ryngeal (15), oral cavity (5) or hypopharynx (4) SCC. This phase I-II study
confirmed the low toxicity of Doxil reported by phase I study. However,
a moderate response (17%) was obtained and no response was achieved in
patients with DMs[71].
Other clinical studies were performed using a liposomal formulation of
cisplatin, one of the most used chemotherapeutic agent in OSCC (see 1.1.2).
A phase I study was first conducted by Rosenthal et al.[73] on 20 patients
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with stage IVa\b HNSCC treated with liposomal cisplatin concurrent with
radiotherapy. No ototoxicity, neurotoxicity, and nephrotoxicity of the treat-
ment with liposomal cisplatin were reported. Eight patients experienced a
CR. However, further dose escalation was stopped by the sponsor because
the liposomal cisplatin was not able to reach a high concentration within
the tumor, resulting in a limited clinical efficacy [73]. More recent stud-
ies were performed with another liposomal cisplatin (lipoplatin) by Jehn et
al.[74, 75]. In this phase III study, 25 and 21 patients with stage IV HNSCC
were treated with lipoplatin plus 5-FU and cisplatin plus 5-FU respectively.
Less renal toxicity, neurotoxicity, hematoxicity, and mucositis were reported
in the group treated with lipoplatin than the one treated with cisplatin.
However, patients treated with lipoplatin experienced more grade III ane-
mia and grade IV neuropathy. At the therapeutic level, less stable disease
(50% vs 64%) and more PR cases (38.8% vs 19%) were observed in the
cisplatin group than in the lipoplatin one[74]. One of the reasons for this
difference may be a different pharmacokinetics between the two compounds.
Indeed, another study reported a higher total platinum plasma concentra-
tion, a shorter half-life and a higher plasma clearance of lipoplatin than
cisplatin[75].
Paclitaxel-albumin NPs were administered intraarterially in 31 patients
with advanced HNSCC[76]. In this study, the toxicity of paclitaxel NPs was
acceptable and CR and PR were observed in 10.34% and 65.51% of cases
respectively[76].
Only one study included only patients (n=23) affected by tongue SCC.
All patients were treated intraarterially with paclitaxel NPs. The adminis-
tration of the paclitaxel NPs resulted in 8.6% of hematoxicity and neuro-
toxicity cases. The overall response rate was 76.5-83.3%[77].
Another type of NPs encapsulating paclitaxel (cationic liposomes) was
used in one small clinical study by Strieth et al.[78]. In contrast to conven-
tional liposomes and paclitaxel, cationic liposomes are capable of targeting
the tumor endothelial cells, resulting in an anti-vascular effect within the
tumor. The preliminary results of this first study revealed a good safety
profile of the cationic liposomes loaded with paclitaxel[78].
Finally, another recent study[79] administered NPs albumin-bound pacli-
taxel combined with cetuximab, cisplatin, and 5-FU followed by cisplatin
and radiotherapy in 30 patients, most with oropharyngeal (n=18) or la-
ryngeal (n=9) SCC. The majority of the patients had a large primary tu-
mor (T3, T4) and lymph node metastases. Seventeen patients had HPV+
oropharyngeal SCC. Severe adverse effects occurred in 30% of the patients,
while a complete clinical response of the primary tumor site was obtained
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in 63% of the patients with oropharyngeal SCC (14 patients) after 2 cycles
of paclitaxel NPs plus cetuximab. In addition, a CR of 30% and a PR of
48% were obtained at the site of lymph node metastasis[79].
The clinical studies performed on nanomedicine drugs and others currently
underway indicate the emerging of these systems as possible therapeutic
strategies for OSCC therapy[112]. In the clinical studies reported[63, 76, 77],
NPs demonstrated few collateral effects and were easier to handle than free
drugs. However, most of the clinical trials reported the use of first-generation
nanomedicine drugs, which are not able to accumulate in high concentra-
tions within the tumor (lipoplatin) or to target metastatic sites (Doxil and
lipoplatin). Further clinical trials with more sophisticated platforms are
needed in order to achieve more therapeutic efficacy against metastatic sites.
Preclinical studies
In contrast to clinical studies, several preclinical studies have been published
for OSCC therapy. Despite most of these studies evaluated the NPs systems
only in vitro, some of them used more sophisticated platforms with active
targeting or stimuli-responsive components[59].
In addition to the published clinical trials [63, 70, 71, 72], different nanofor-
mulations of doxorubicin were also evaluated on HNSCC cells and in vivo.
These formulations consisted of the combination of doxorubicin with resvera-
trol[80], methotrexate [81, 82, 83] or an autophagy inhibitor[84]. In vitro, the
drug combination was more effective than the free form and nanoformulation
of the single drug, resulting in an increase of chemosensitivity[84]. In vivo,
the administration of liposomes loaded with doxorubicin and methotrexate
decreased the expression of VEGF and Matrix Metalloproteinases (MMPs)
in a NQO-induced oral cavity SCC rat model[81, 82, 83]. Regarding cis-
platin, ligand-decorated cancer-targeted polymeric NPs loaded with cis-
platin were more cytotoxic in oral cavity SCC cells than non-targeted NPs
and free cisplatin, due to a higher uptake[85]. In contrast, cisplatin was more
cytotoxic than polymeric micelles loaded with cisplatin (NC-6004) in another
study by Endo et al.[86]. In a SC xenograft model, the NC-6004 demon-
strated less renal toxicity than free cisplatin, while NC-6004 was more effec-
tive against lymph node metastases in an orthotopic xenograft mouse model
of OSCC metastasis[86]. Finally, 5-FU was encapsulated in self-assembled
nucleoside NPs by Zhao et al.[87]. The system exhibited low toxic effects
on normal human oral cells. In addition, the NP formulation presented a
long-term effect and less toxicity in vivo than free 5-FU[87].
The stimuli-responsive properties of magnetic NPs have also been explored
in the preclinical setting. An in vivo study[88] reported that gold NPs with
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laser had more antitumor efficacy than gold NPs alone in a DMBA-induced
oral cavity SCC hamster model. Melancon et al.[89] targeted gold nanoshells
for EGFR through the addition of cetuximab. In vitro, the application
of near-infrared (NIR) light activated the gold nanoshells, reducing signif-
icantly the cell viability compared with the nanoshells alone. In addition,
the cellular uptake of the targeted NPs was higher than non-targeted NPs.
Other types of magnetic[90, 91] and polymeric NPs[92] coupled with pho-
tothermal/photodynamic therapy (PDT) had similar results. Another sys-
tem consisting of a stimuli-responsive titanium dioxide NPs targeted against
EGFR was tested in vivo by Lucki et al.[93]. The system plus laser treat-
ment exerted a high antitumor effect compared with NPs alone and a low
toxicity on a SC model of OSCC. Another study[94] reported similar re-
sults in vivo using photocatalytic titanium dioxide NPs combined with high
intensity focused ultrasound (HIFU). Finally, novel hybrid NPs were devel-
oped by Sathapaty et al.[95] to kill OSCC stem cells. In vitro, the NPs were
able to disrupt OSCC spheroids and to induce apoptosis also of the cancer
stem cells, characterized by a high self-renewal capability. In vivo, a high
anti-angiogenic effect of the NPs was observed in a Chick Chorioallantoic
Membrane (CAM) model[95].
Gene therapy with lipid-based NPs has also been reported in OSCC with
promising results. In a study by Miao et al.[96] PEI-modified Fe3 O4 NPs
were used to deliver human TNF-related apoptosis-inducing ligand (TRAIL)
gene with an hTERT tumor-specific promoter (pACTERT-TRAIL). More
in vitro cytotoxicity and a higher transfection efficacy were obtained than
conventional PEI\lipofectamine. The platform obtained positive results also
in a SC model of OSCC[96]. Two more recent studies[97, 98] reported the
use of lipid-calcium-phosphate (LCP)- NPs loaded with HIF1α or VEGF
siRNA combined with photosan-mediated PDT. Photosan has been used as a
photosensitizer drug and is locally administered after the laser treatment. To
increase the efficiency of PDT, which usually requires multiple treatments,
LCP-NPs were also actively targeted against σ receptors[97, 98], expressed
by HNSCC. A higher cytotoxic activity and cellular uptake were obtained
using targeted NPs compared with non-targeted NPs. In vivo, HIF1α lipid
NPs plus PDT reported more efficacy than scrambled siRNA LCP plus PDT
in a SC model of OSCC[98]. A similar in vivo efficacy was also reported
by Lecaros et al.[97] who used σR-targeted LCP-NPs to deliver VEGF-A
siRNA with and without PDT compared with scrambled siRNA with and
without PDT.
Finally, NPs with natural plant compounds have been also developed for
OSCC. Indeed, plant products are rich in flavonoids and stilbenes, which ex-
ert antitumor effects[5]. NPs can overcome the poor solubility and bioavail-
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ability showed by these compounds in the clinic[5]. In OSCC, NPs encapsu-
lating curcumin, naringenin, genistein, and salvianolic acid B were tested in
vitro and in vivo. The nanoformulation of curcumin decreased chemoresis-
tance in a cisplatin-resistant cell line and increased the cellular uptake com-
pared with the free form[98]. Stimuli-responsive nanocarriers with curcumin
were also used in combination with a laser[100] or ultrasonography[101], re-
sulting in a lower cell viability and a higher down-regulation of VEGF,
MMP-9, and NF-κB than free curcumin and nanocarriers alone[100, 101].
In addition, Mazzarino et al.[102] prepared mucoadhesive polycaprolactone
(PCL) NPs loaded with curcumin and a chitosan-coating for the local treat-
ment of OSCC. The platform was able to induce apoptosis in tongue cancer
cells[102]. Similar efficacy was obtained by Gavin et al.[103] with the mu-
coadhesive NPs loaded with genistein compared with aqueous nanoemulsions
of genistein. In addition, the malignant transformation of oral cells was pre-
vented in the group treated with NPs encapsulating genistein compared to
controls and free genistein group in a DMBA-induced model of OSCC[104].
This effect is known as chemoprevention. Finally, a nanoformulation of sal-
vianolic acid was able to decrease the cell growth in oral precancerous and
OSCC cell lines compared with the free form[105].
In conclusion, advanced and/or metastatic OSCC is still a fatal disease
with a poor survival rate, especially when DMs occur. Recently, nanomedicine
has changed the cancer treatment, contributing in some cases to an in-
crease of OS and the quality of life[61, 62]. Despite the few toxic effects re-
ported compared with the free form of anticancer drugs, the first-generation
nanomedicine drugs report some limitations not only in targeting the pri-
mary tumor site but also metastatic ones[71, 73]. These findings are observed
in patients affected by HNSCC.
In the preclinical setting, there are several published studies on the use of
second-generation nanomedicine compounds for OSCC therapy. However,
most of them reported only an in vitro evaluation, which may not reflect
the in vivo one, particularly in the case of metastases[29]. In addition, the
majority of the study used a SC xenograft model of OSCC, which does
not resemble the behavior and clinical response of OSCC[31]. Orthotopic
models were used in a few cases. Only the study by Endo et al.[86] reported
an anti-metastatic effect of a nanoformulation of cisplatin against lymph
node metastases. Therefore, more efforts are warranted in order to develop
and to evaluate novel nanomedicine platforms in more appropriate animal
models of OSCC, including also models of OSCC metastasis.
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1.3 Aim of the dissertation
The aim of the work reported in the present dissertation was to establish
mouse models of OSCC metastasis that may be then used to evaluate inno-
vative and promising anti-metastatic platforms such as iNPG-pDox. Indeed,
iNPG-pDox presented a promising efficacy against lung metastases, the most
frequent DMs reported in OSCC(see 1.1.3). In addition, iNPG-pDox is
a third-generation nanomedicine drug, which has never been reported for
OSCC therapy.
In a first experiment, the efficacy of the platform was evaluated in vitro
on an OSCC cell line (HSC-3). This cell line was chosen because of its
derivation from a tongue SCC with a high metastatic potential. For these
studies, only the pDox NPs, without iNPG, were used due to the capability
of iNPG to target lung metastases in vivo only by natural tropism. In
addition, pDox NPs were reported to enter the tumor interstitial space,
after being generated in situ[66]. This cell line was treated with pDox NPs
and the free form of doxorubicin and the viability was evaluated after 72 and
96 h of treatment. After that, qualitative uptake studies were performed at
different time points in order to evaluate the internalization of pDox NPs in
the HSC-3 cell line compared to doxorubicin.
After proving the capability of pDox NPs to kill the HSC-3 cells, pi-
lot studies were conducted to establish an orthotopic model of OSCC lung
metastasis. Indeed, the orthotopic model of OSCC is still considered the
most similar to human OSCC. In addition, the majority of the orthotopic
models of OSCC metastasis presents a low rate of lung metastasis (see Ta-
ble 1.2). In this experiment, the primary tumor and/or the lung metastases
were evaluated by in vivo and ex vivo imaging techniques, as well as his-
tology and immunohistochemistry (IHC). Both sexes of athymic nude mice
were used to establish the model and promising results were obtained using
male mice, in which a high prevalence of lung metastases was observed.
In addition, a second model of OSCC metastasis was established through
IV injection. Indeed, this model is widely used to establish lung metastases
of several types of cancer and presents a rapid growth and a high repro-
ducibility. In addition, this model has not been frequently used in OSCC
research and no serial transplantations have been reported (see Table 1.2).
Indeed, the first experiment with IV injection of HSC-3 cells resulted in the
growth of large lung metastases in one mouse. From these lung metastases,
a new cell line (HSC-3 M1) was isolated and was injected IV in other 5
athymic nude mice. In this model, a high rate of lung metastases was ob-
tained. HSC-3 M1 cell line was also treated with pDox and doxorubicin and
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the results did not significantly differ from those obtained on the parental
cell line, suggesting a potential efficacy of pDox NPs also against tumor cells
isolated from lung metastases.
Chapter 2
Viability assay and pDox
uptake in OSCC cells
2.1 Materials and Methods
Cell line Human HSC-3 cell line was obtained from the Japanese Collec-
tion of Research Bioresources Cell Bank (n◦JCRB0623). HSC-3 cells derives
from a tongue SCC with a high metastatic potential. Cells were cultured in
DMEM with 10% fetal bovine serum (FBS) plus 1% penicillin-streptomycin
(PS) at 37◦C in a humidified atmosphere of 5% CO2 and 95% air.
Synthesis of pDox nanoparticles pDox was synthesized by Guodong
Zhang according to Xu et al.[65]. Briefly, a conjugation with hydrazide
groups to glutamic acid side chains of poly(L-glutamic acid) was performed
through an acid anhydride reaction as the following: isobutyl chlorformate
was dropwise added at 4◦C to a DMF solution of poly(L-glutamic acid) and
N-morphylmorline. After 15 minutes, carbazic acidtert-butyl ester in DMF
was added to the solution. The reaction occurred initially for 30 minutes
at 4◦C. Then the solution was placed at 25◦C for 2 h. The polymer was
synthesized dissolving poly(L-glutamic acid hydrazide)-co-poly(L-glutamic
acid) in anhydrous methanol with the addition of trifluoro-acetic acid. Af-
ter that, doxorubicin hydrochloride was added and the final product was
allowed to stir at 25◦C for 2 days under Argon gas. pDox was then concen-
trated, dialyzed in methanol and purified by using Spehadex-LH20 (Amer-
sham Pharmacia Biotech Co).
Preparation of pDox nanoparticles and measurement of size pDox
NPs were obtained by suspending pDox in DMF at a concentration of 10
mg/ml. The pDox DMF solution was then resuspended in PBS. The size of
pDox NPs was measured in PBS using Zetasizer Nano-ZS (Malvern Instru-
ments Ltd).
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MTS Assay HSC-3 cells were plated in a 96-well plate (4 x 103 cells
per well) and incubated for 24 h to allow cell adhesion. HSC-3 cells were
then treated with different concentrations of free doxorubicin. Equimolar
amounts of doxorubicin in polymeric form were used. After 72 and 96 h,
cells viability was evaluated through MTS assay (Promega) according to the
manufacturer′s protocol. The absorbance of the samples was measured at
490 nm using a Synergy H4 hybrid reader.
Uptake studies of pDox nanoparticles and free doxorubicin For
uptake studies, HSC-3 cells (2 x 104 cells per chamber) were seeded on 4-
well chamber slides (BD Falcon) and incubated for 24 h. Cells were then
treated with 5 µM of free doxorubicin and equimolar amounts of pDox NPs
for 1, 6 and 24 h. The cells were then washed three times with PBS and
fixed in paraformaldehyde for 20 minutes. Actin cytoskeletal microfilaments
were stained with Alexa Fluor 488 phalloidin (Invitrogen, 1:200; excita-
tion\emission:495\518 nm) and DAPI (4 µg/ml; incubation time of 3 min-
utes) was used to stain the nucleus. Finally, cells were washed three times
with PBS and slides were mounted with ProLong Gold Antifade Mountant
(Invitrogen). Z-stack images were then collected using a confocal micro-
scope (Nikon A1 Confocal Imaging system) at 0.51 (treatment groups) or
1.10 µm intervals (control group). Doxorubicin was detected in the groups
treated with free and pDox NPs using the propidium iodide (PI) channel
(excitation\emission: 543\619 nm). The images were further elaborated
with ImageJ software.
Statistical analysis Statistical analyses were performed using one-way or
two-way analysis of variance (ANOVA) with the GraphPad Prism software.
Differences at p < 0.05 were considered to be statistically significant.
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2.2 Results
As stated in the 1.3, the present in vitro study performed on HSC-3 cells
consisted of a viability assay and a qualitative uptake study. The viabil-
ity assay after the treatment with different concentrations of doxorubicin
permitted to confirm that HSC-3 cells were sensitive to doxorubicin. After
that, the effect of pDox NPs on the cells viability was investigated. The
treatment with the highest concentration of pDox NPs resulted in a cell vi-
ability below 40%, proving that also pDox NPs were able to kill HSC-3 cell
line. The internalization of pDox NPs was then confirmed by confocal mi-
croscopy, although it was delayed compared to the free form of doxorubicin.
This difference in uptake between doxorubicin and pDox NPs may explain
the one observed in cytotoxicity.
2.2.1 Viability assay for HSC-3 cells after treatment with
doxorubicin and pDox NPs
Results obtained from MTS assay of HSC-3 cells treated with 0, 0.0001,
0.001, 0.1, 0.5, and 1 µM of doxorubicin hydrochloride are summarized in
Fig. 2.1. The cell viability of HSC-3 cells significantly decreased after the
treatment with the highest concentrations of doxorubicin (0.1, 0.5 and 1 µM)
at both time points. In addition to a dose-dependent effect, doxorubicin
exerted a time-dependent effect on cell viability. Indeed the cells treated for
96 h had a lower viability than those of cells treated for 72 h. However, this
difference was not statistically significant.
The procedure of making pDox NPs is reported in the Material and Meth-
ods. In Table 2.1, different measurements of the size of pDox NPs are re-
ported. Measurements were performed using intensity average. The average
size of pDox NPs was 111.85 ± 4.36 nm. Results are reported as mean ±
SD.
Fig. 2.2 represents the cellular viability assay performed after 72 and
96 h of treatment with doxorubicin and pDox NPs (Fig. 2.2 a, b). In
contrast with the free form of doxorubicin, only the treatment with the two
highest concentration of pDox NPs (0.5 and 1 µM) resulted in a significantly
lower cell viability than controls at both time points (Fig. 2.2 a, b). Indeed,
pDox NPs were significantly less cytotoxic than the free form of doxorubicin.
However, this difference in cytotoxicity decreased after 96 h of treatment
with 0.5 and 1 µM of pDox NPs (Fig. 2.2 b), proving that both pDox NPs
and free form of doxorubicin were able to effectively kill HSC-3 cells. As the
free form of doxorubicin, the effect of pDox NPs on cell viability was dose-
and time-dependent (Fig. 2.2 a, b).
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Table 2.1: pDox NPs size measurement
Dispersant pDox Z-Ave (d.nm) PdI
PBS 111.9 ± 1.305 0.097 ± 0.045
PBS 113.7 ±1.266 0.138 ± 0.017
PBS 103.9 ± 2.650 0.136 ± 0.017
PBS 117.9 ± 2.196 0.084 ± 0.046
PBS 112.3 ± 1.888 0.109 ± 0.018
PBS 109.3 ± 0.854 0.089 ± 0.028
PBS 113.9 ± 0.838 0.122 ± 0.017
Legend: Z-Ave = z-average size; PdI= polydispersity index
2.2.2 Cellular uptake study of pDox NPs and free doxoru-
bicin in HSC-3 cells
The cellular uptake study reported in Figg. 2.3-2.4 reveals that pDox NPs
presented a delayed entry into HSC-3 cells compared with the free form of
doxorubicin after 1, 6 and 24 h of treatment. In the group treated with pDox
NPs, doxorubicin localized within the nucleus after 6 and 24 h of treatment
(Fig. 2.3 b and Fig. 2.4). In contrast, doxorubicin was already observed
within the nucleus of HSC-3 cells after 1 h of treatment with the free form
of doxorubicin (Fig. 2.3 a).
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(a)
(b)
Figure 2.1: Viability assay results for HSC-3 cell line after 72 (a) and 96
h (b) of treatment with different concentrations of doxorubicin. Data are
expressed as the mean ± SEM of at least three experiments. ∗∗∗ P ≤0.001,
∗∗∗∗P ≤ 0.0001 by one-way ANOVA statistical analysis and Dunnet′s mul-
tiple comparisons test.
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(a)
(b)
Figure 2.2: Viability assay results for HSC-3 cell line after 72 (a) and 96
h (b) of treatment with different concentrations of pDox NPs and the free
form of doxorubicin. Data are expressed as the mean ± SEM of at least
three experiments. ∗∗ P ≤0.01 by one-way ANOVA statistical analysis and
post hoc Tukey test.
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(a)
(b)
Figure 2.3: Z-stack confocal images after 1 (a) and 6 h (b) of treatment with
doxorubicin (free dox) and pDox NPs. Alexa Fluor 488 R© phalloidin (green
fluorescence) was used to stain the cytoskeleton. DAPI (blue fluorescence)
was used to stain the nuclei. Propidium iodide channel (red fluorescence) was
used to detect doxorubicin in the free and polymeric form. The pink/purple
fluorescence indicates doxorubicin localized within the nucleus. Scale bar
represents 10 µm.
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Figure 2.4: Z-stack confocal images after 24 h of treatment with doxorubicin
(free dox) and pDox NPs. Alexa Fluor 488 R© phalloidin (green fluorescence)
was used to stain the cytoskeleton. DAPI (blue fluorescence) was used
to stain the nuclei. Propidium iodide channel (red fluorescence) was used
to detect doxorubicin in the free and polymeric form. The pink/purple
fluorescence indicates doxorubicin localized within the nucleus. Scale bar
represents 10 µm.
Chapter 3
An orthotopic model of
OSCC metastasis
3.1 Materials and Methods
HSC-3 cell line transfection A stable HSC-3 cell line expressing lu-
ciferase (Luc) and GFP was generated using a lentivirus carrying both genes.
Briefly, HSC-3 cells were plated in a 6-well plate (72 x 103cells per well).
After 24 hours, 500 µl of new media without antibiotics with polybrene
(2x) and 500 µl of lentivirus were added. After an incubation time of 15
hours, the media was changed. The selection of transfected cells was ini-
tially performed by treating transfected and control cells with 0.5 µg/ml of
puromycin, to which transfected cells were resistant. Non-transfected cells
served as controls. After 6 days of treatment, the cells were allowed to
grow in normal media (DMEM 10% FBS plus 1% PS) and GFP expression
was evaluated by an inverted digital fluorescence microscope (EVOS FLTM,
American Microscope Group).
Cell sorting and evaluation of luciferase expression HSC-3 GFP/Luc
cells were selected for GFP expression by Fluorescence Activated Cell Sort-
ing (FACS) using BD FACSAria II Cell Sorter. Before sorting, the cell
suspension was filtered using a 40 µm cell strainer (FisherbrandTM). Sorted
HSC-3 GFP/Luc cells were then cultured in DMEM 10% FBS plus 2% PS
for the first 5 days. After that, the cells were cultured in normal media.
The expression of Luc was confirmed as follows: different concentrations
of HSC-3 GFP cells were plated in a 96-well plate in 100 µL of media and 50
µL of D-luciferin (15 mg/ml) were added to each well. DMEM media was
used as a negative control. The Luc expression was then evaluated by IVIS
Spectrum In-Vivo Imaging System (Perkin Elmer Inc., Waltham, MA).
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Orthotopic mouse model All animal experiments were performed with
a protocol approved by the Institutional Animal Care and Use Committee
(IACUC) at the Houston Methodist Research Institute and in accordance
with the National Institutes of Health Guide for the Care and Use of Labo-
ratory Animals.
For this experiment, athymic nude-Foxn1nu mice (Envigo), male (n = 5)
and female (n = 10), 5-6 weeks old (male weight 25.30 ± 2.20; female weight
21.35 ± 1.03) were used. The animals were maintained in individually ven-
tilated cages (Tecniplast) with controlled air flow in light controlled rooms
(12 hours of light). After the transplantation of tumor cells, the mice were
fed with water and soft food ad libitum. The soft food diet consisted of
moistened pellet and DietGel (ClearH2O).
For the orthotopic mouse model, HSC-3 GFP/Luc cells were trypsinized
and suspended in PBS. Thirty minutes before the procedure, analgesia was
provided to the animals by a SC injection of buprenorphine SR (1 mg/kg).
The animals were induced with 3% isoflurane and maintained with 2.5%
isoflurane. The tongue was exposed using a 10 cm forceps (Robox Surgical)
and 5 x 104 HSC-3 GFP/Luc cells suspended in 20 µl of PBS were slowly
injected into the left side of the tongue submucosally using an insulin syringe
with 28G 1/2 needle. After the procedure, the experimental animals were
monitored and weighed periodically. The animals were humanely sacrificed
before the endpoint of the experiment (6 weeks and 11 weeks after injection
for females and males respectively) when they presented 20% of weight loss,
severe dehydration, inappetence, facial deformation, and/or malocclusion.
Evaluation of the growth of the primary tumor and distant metas-
tases The growth of the primary tumor and lung metastasis were periodi-
cally visualized using IVIS Spectrum In-Vivo Imaging System (Perkin Elmer
Inc., Waltham, MA). Briefly, 200 µl of D-luciferin (15 mg/kg) were adminis-
tered to each mouse intraperitoneally 10 minutes before the imaging. Mice
were induced with 3% isoflurane in 100% oxygen and then maintained under
2% isoflurane. In order to visualize the lung metastases, the primary tumors
were covered with a black sheet.
The growth of the primary tumor was then quantified defining the biolumi-
nescence region of interest (ROI). Data were reported as p/s/cm2/sr/(µW/cm2)
as per the instructions (PerkinElmer, USA).
Mice sacrifice, harvesting of tissues and staining Eight and eleven
weeks after the injection, female and male mice were humanely sacrificed re-
spectively through an overdose of isoflurane followed by cervical dislocation
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to confirm the death. At necropsy, the tongue, the mandibular lymph nodes
with the salivary glands, the lungs, the liver, and the spleen were collected
from each mouse. The presence of the tumor and metastases was evaluated
by IVIS of the mice organs.
After the imaging, the organs were fixed in Bouin′s solution for 12 hours
(lungs) or in 10% buffered formalin for 48 hours (all the other tissues).
The tissues were then embedded in paraffin and processed for hematoxylin
and eosin (H&E) staining (two sections per organ). Pictures of the tongue
tumor, lymph node and/or lung metastasis were captured using an upright
microscope system (Nikon Eclipse 80i). Oral cancer metastases (two sections
per organ) were further confirmed through immunohistochemistry (IHC) for
anti-human mouse monoclonal pan-cytokeratin (pan-CK) antibody (Dako).
Statistical analysis Survival analysis was performed by the Kaplan-Meier
method and a comparison between survival curves was performed using the
log-rank test.
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3.2 Results
The present in vivo pilot study consisted of the establishment of an ortho-
topic model of OSCC in both sexes of athymic nude mice. Indeed, it is
well known that this model resembles the metastatic potential and tumor
growth of human OSCC. For these experiments, the HSC-3 GFP/Luc cell
line was used in order to investigate a possible development of lymph node
and lung metastases. As a result, regional lymph node metastases were
present in more than 50% of the animals which developed the primary tu-
mor. Interestingly, the presence of lung metastases was observed by ex vivo
IVIS in 60% of male mice, one of which presented large metastatic nodules.
However, only 20% of the female mice developed small lung metastases. His-
tology and IHC for pan-CK were also performed to confirm the metastases
in the lungs and in the lymph nodes.
3.2.1 Generation of a stable HSC-3 cell line expressing GFP
and luciferase
Images of transfected HSC-3 cells selected with puromycin and control cells
are reported in Fig 3.1 a. However, only 1% of transfected HSC-3 cells
presented a good expression of GFP at the sorting (Fig. 3.1 b). The ex-
pression of Luc of sorted HSC-3 GFP cells was also evaluated using In Vivo
Imaging Spectrum (IVIS) (Fig 3.1 b). As expected, sorted HSC-3 GFP cells
expressed also Luc and the intensity of the bioluminescent signal correlated
with the cellular concentration.
3.2.2 Mice survival
All males (n = 5) survived after the tongue injection and all of them de-
veloped the tongue tumor. The weight of the mice did not decrease after
the procedure. Two male mice (508, 512) who presented weight loss, poor
BCS and dehydration were sacrificed 43 and 54 days after the injection.
Another male mouse (510) died 60 days after the injection due to the lung
metastases. The other two mice (507, 509) were sacrificed 11 weeks after
the injection.
All females (n =10) survived after the procedure without any complica-
tions. Two mice (030, 089) did not develop the primary tumor. The mouse
081 was sacrificed for head tilt and left circling due to a bacterial infection
(B. Gladioli) 41 days after the injection. Five mice with weight loss and
poor BCS were sacrificed on day 32 (094), day 34 (095), day 36 (090, 097),
and day 44 (083). The last two mice (080,096) were sacrificed 8 weeks after
the injection.
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(a)
(b)
Figure 3.1: Fluorescence microscopy and FACS of transfected HSC-3 cells.
a) Control and transfected HSC-3 cells, fluorescence microscope. Scale bar
represents 400 µm. b) Flow cytometry analysis for GFP expression and
IVIS.
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The median survival of male mice was 60 days, in contrast with female
mice, whose median survival was 43.5 days (Fig. 3.2). However, this differ-
ence was not statistically significant.
3.2.3 Development of the primary tumor
The growth of the primary tumor was periodically evaluated by IVIS (Fig.
3.3 a, b) in all the animals injected. However, a difference in tumor growth
was observed among the animals (Fig. 3.3 and 3.5). Indeed, 4 male mice
developed the tongue tumor 30 days after the injection, while the mouse
510 began to develop the tumor 43 days after the injection (Fig. 3.3 a).
This finding is more evident in the graph of Fig. 3.4, which represents the
average radiance of the signal of each tumor. In addition, only two mice
(508, 512) presented a large tumor (> 7.5 x 106 p\s\cm2\sr) and the mouse
512 had also large lymph node metastases. The signal grew progressively
in 3 mice, while it seemed to be irregular in the mice 507 and 509, whose
peaks of growth were at day 64 and 50, respectively. After that day, the
signal decreased in both mice.
Regarding the females, 2 of 10 mice (030, 089) did not develop the primary
tumor 31 days after injection (Fig. 3.3 b and 3.5). The tumor seemed
to regress completely in the mouse 096 between 43 and 50 days after the
injection and partially in the mouse 080 between day 37 and 43 (Fig. 3.3
b). Despite this irregular growth, the quantification data in Fig 3.4 show a
homogenous signal of the tongue tumor until day 50 (> 7.5 x 106 p\s\cm2\sr)
.
3.2.4 Presence of lung and lymph node metastases
The first signal of lung metastases was observed 30 days after the injection
only in one male mouse (Fig. 3.6 a). From day 50 the bioluminescent signal
from the lungs was visible together with the primary tumor. The metastases
continued to grow until the death of the animal, which occurred 60 days after
the injection. Interestingly, the primary tumor was very small at the time of
the first evidence of lung metastases (Fig. 3.4 and Fig. 3.6) and its growth
was relatively slow until day 50 (Fig. 3.3 a). No evident lung metastases
were observed in the surviving two mice (Fig. 3.6 a). In contrast to the male
mice, lung metastases did not become evident in female nude mice (Fig. 3.6
b).
Regarding the lymph node metastases, they were observed as a separate
signal only in few male nude mice: the mouse 512 developed regional lymph
node metastasis from 22 days after the injection, while a small signal was
observed in the mouse 509 43 days after the injection. However, the signal
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(a)
(b)
Figure 3.2: Results of the animal study: survival of the male (a) and female
nude mice (b) by Kaplan-Meyer analysis.
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(a)
(b)
Figure 3.3: IVIS of the tongue tumor in male (a) and female (b) athymic
nude mice: the growth of the primary tumor was observed in male and female
athymic nude mice 22 days and 31 days after the injection respectively. The
presence of regional lymph node metastases was observed in two male mice.
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Figure 3.4: IVIS of the tongue tumor and quantification of the biolumines-
cence signal in males (graphs above). Quantification data for each mouse
are reported. The graphs below report the signal and the quantification in
females. Data are expressed as the mean±SD. The rectangle delimitates
the region of each subject. The red circle represents the ROI for the tongue
tumor.
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Figure 3.5: Representative pictures of the primary tongue tumor in nude
male (1) and female mice (2) at different time points. The left middle portion
of the tongue appeared enlarged in most animals. Fig. g) represents a mouse
without the primary tumor. The tumor was identified by the discoloration
of the tongue. Ulcerations of different dimensions were also present in some
cases (1: a, e; 2: b, h). In a mouse, the ulceration occupied part of the left
margin of the tongue(Fig f, i).
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(a)
(b)
Figure 3.6: IVIS for lung metastases in male (a) and female athymic nude
mice (b): the mouse 510 presented large lung metastases 30 days after the
injection. Lung metastases were not detected in females from 31 to 50 days
after the injection.
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decreased after day 58 (Fig. 3.3 a). As mentioned previously, the primary
tumor of these two mice had different dimensions and a different growth (Fig.
3.4). No clear signal from regional lymph node metastases was observed in
females (Fig. 3.3 b).
3.2.5 Necropsy and ex vivo IVIS of mice organs
Representative pictures of the tongue tumor, lymph node metastases, and
lungs at necropsy are reported in Figg. 3.7 - 3.8. The tongue tumor was
mainly located on the left side of the tongue, but in several cases, the right
side was also involved, especially in females (Fig. 3.8). The tumor presented
as a medium-large yellowish-whitish mass with undefined margins in the
middle and anterior portion of the tongue. In a few cases, ulcerations were
present (small arrows). Lung metastases were not clearly macroscopically
observed, except for the mouse 510. Indeed, this mouse presented several
coalescent large white metastatic nodules in the lungs 60 days after the
injection (Fig. 3.7). Lymph node metastases were macroscopically evident
in some animals as yellow masses with undefined margins (small arrows).
Ex vivo IVIS of the tongue, regional lymph nodes, lung, spleen, and liver
was also performed to show the presence of tumor and metastases (Figg.
3.7 - 3.8). The tongue tumor was evident in all the 4 nude male mice.
Interestingly, the mice 508 and 512 sacrificed at early time points (43-55 days
after the injection) presented larger tongue tumors than those of the animals
507 and 509, sacrificed 77 days after the injection (Fig. 3.7). In addition, the
mice 508 and 512 in which lung metastases were not observed at IVIS (Fig.
3.6 a), presented metastatic nodules in the lungs. In addition, lymph node
metastases were detected in 3/4 mice by ex vivo IVIS. Interestingly, the mice
with lung metastases (508 and 512) presented large lymph node metastases,
in contrast to the mouse 507 which had a small one. The metastases involved
principally the left regional lymph nodes. In the mouse 512, some tumor
cells were visible also in the right regional lymph node (Fig. 3.7).
In female nude mice, large tongue tumors were observed 32-34 days (Fig.
3.8, mice 094, 095) and 56 days after the injection (Fig. 3.8, mouse 080). No
tongue tumor was detected in mice 030, 089 and 096. Lung metastases were
observed only in two mice (Fig. 3.8, mice 094 and 080) and they were smaller
than the ones in male mice (Fig. 3.7, mice 512 and 508). Also in females, the
mice with lung metastases had lymph node metastases, one of which was
bilateral (Fig. 3.8, mouse 080). Four more female mice presented lymph
node metastases, while no metastases were detected in the mice without the
primary tumor.
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Figure 3.7: Necropsy and ex vivo IVIS of male mice tumor and organs.
Representative pictures of the tongue (T), regional lymph nodes with sali-
vary glands (LN) and lungs (L) of all 5 mice (507-510, 512). Large lung
metastases observed in mouse 510 (arrows). Ex vivo IVIS of the tongue (T),
lymph node (LN), lungs (L), liver (LV), and spleen (S) of 4 mice. Black and
white arrows indicate the presence of lymph node and lung metastases re-
spectively. Lung and lymph node metastases were observed macroscopically
or by IVIS in 3/5 mice. No liver metastases were observed.
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Figure 3.8: Necropsy and ex vivo IVIS of female mice tumor and organs.
Representative pictures of the tongue (T), regional lymph nodes with sali-
vary glands (LN) and lungs (L) of 6 mice. Ex vivo IVIS of the tongue (T),
lymph node (LN), lungs (L), liver (LV), and spleen (S) of 6 mice. Black and
white arrows indicate the presence of lymph node and lung metastases re-
spectively. Lung metastases were observed in 2\7 mice. No liver metastases
were observed.
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3.2.6 Histology and immunohistochemistry
The presence of the tongue tumor and metastases was further confirmed
by H&E and staining for human CK. Representative images of the tongue
tumor, regional lymph node, and lung metastases are reported in Figg. 3.9
- 3.17.
Primary tumor
In the tongue, the tumor was mainly located in the middle portion. The
anterior portion of the tongue was involved in some cases, especially in
females (Fig. 3.10). The difference in the dimension and intensity of signal
between the tongue tumors observed by ex vivo IVIS in male mice (Fig.
3.7) was histologically confirmed (Fig. 3.9). In the large tumors, the growth
was highly infiltrative with the invasion of the deep muscular layers. In the
mice sacrificed at late time points (507 and 509), the tumor was smaller
and was located only in the superficial layers of the muscle (Fig. 3.9 a,
b). Interestingly, the mouse 509, whose tumor signal was decreased by IVIS
(Figg. 3.3 - 3.4) seemed to be capsulated (Fig. 3.9, g-h). In contrast, there
was no difference between the tongue tumors in female athymic nude mice.
As previously observed by IVIS, all the tumors extended from the middle
to the anterior portion of the tongue. In some cases, histological analysis of
the primary tumors showed infiltration of the deep muscular layers close to
the ventral epithelium (Fig. 3.10).
The cellular architecture was similar among the tongue tumors developed
in both male and female nude mice and it was typical of a moderate/poorly
differentiated OSCC. Indeed, most tumor cells formed several islands and/or
cellular cords surrounded by some stroma. Few keratinization areas were
present (Fig. 3.9, a-d; Fig. 3.10, a, e). At a greater magnification, tumor
cells exhibited several features of malignancy in both sexes of mice: round
to spindle morphology (pleomorphism), altered nuclear-cytoplasmic ratio,
anisocytosis, anisokaryosis, prominent and/or multiple nucleoli, and nuclear
atypia (Figg. 3.9-3.10).
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 3.9: Representative pictures of tongue tumors in male athymic nude
mice at different magnifications (40x, 100x, 400x): a-c represent a small
tongue tumor, observed 11 weeks after the injection (40x, 100x, 400x). Tu-
mor cells were organized in nests and presented keratinization. The tongue
tumor at early time points (d-f) was highly invasive and it extended into the
ventral portion of the tongue. Cancer cells were grouped in nests or in cord-
like structures surrounded by abundant stroma. Atypia and keratinization
(white arrows) were also present. In the mouse 509 (g-h), the tumor was
located in the superficial layers of the muscle and displayed a high grade
of keratinization. Some lymphocytes and fibrocytes were also present (40x,
100x). DEp= dorsal epithelium, VEp= ventral epithelium.
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 3.10: Representative pictures of tongue tumors in female athymic
nude mice: a-c represent a tongue tumor at 36 days after the injection (40x,
100x, 200x). The tumor presented a high cellularity and a deep infiltration
of the muscle layer. Some keratinized areas were also present (white arrows).
The same extensive growth and keratinization were also observed 44 days
after the injection (d-e; 40x, 100x). In some cases, the apical portion of
the tongue was also invaded by the tumor (g). Tumor cells formed several
cellular islets and presented marked atypia, with pleomorphism and different
nuclear size and shape (h, 400x). Some mitotic figures were also present
(black arrows). DEp= dorsal epithelium, VEp= ventral epithelium.
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(a) (b)
(c) (d)
(e) (f)
Figure 3.11: Representative pictures of the tongue tumor of mouse 510
at 40x, 100x, 400x (a-c): areas with a high cell density and high cellular
keratinization (white arrows) were observed. At 400x, cells presented several
features of malignancy, with a marked pleomorphism and severe nuclear
atypia (black arrows). d-f regional lymph node (40x, 100x, 400x): tumor
cells formed metastatic nodules in the lymph node cortex. At a greater
magnification, tumor cells with large nuclei and prominent nucleoli between
lymphocytes.
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Lymph node and lung metastasis
The presence of lymph node metastases was first evaluated by H&E stain-
ing. Metastatic areas were located in the subcapsular sinus and/or in the
cortex of the lymph nodes, especially in males (Figg 3.11-3-13). In some
cases, tumor cells organized in cell nests formed large nodules surrounded
by lymphocytes (Figg. 3.11-3.12). As in the tongue, nuclear atypia, promi-
nent nucleoli and altered nuclear-cytoplasmic ratio were common features
of the tumor cells in the lymph nodes.
Representative pictures of lung metastases in male (510, 508, 512) and
female mice (094, 080) are reported in Fig. 3.14 and 3.15 respectively. In
the mouse 510, tumor cells infiltrated diffusely the lung parenchyma, forming
also keratin pearls (Fig. 3.14 a,b). In the other two males and in female
nude mice, the cellular invasion of lung parenchyma was less diffuse, with
the formation of metastatic nodules of different dimensions (Fig. 3.14 d-h;
Fig. 3.15 a, b, d). As in the tongue and in the lymph nodes, cells formed
islands in some cases (Fig. 3.14 a, b, e; Fig. 3.15 b) and presented altered
nuclear-cytoplasmic ratio, pleomorphism, and atypia (Fig. 3.14 c, f; Fig.
3.15 d).
Cytokeratin expression
All tongue tumors were strongly positive to CK, with some tumor areas more
positive than the others (Fig. 3.16 d, e). A lower expression of CK was found
in the metastatic cells which invaded the subcapsular sinus and the cortex
in the regional lymph nodes. The expression of pan-CK was cytoplasmic in
the cells of the primary tumor, while metastatic cells expressed CK mostly
on the membrane (Fig. 3.16 j-l).
Also in the lungs, not all tumor cells presented a high expression of CK,
except for the mouse 510, in which several islands of metastatic cells were
strongly positive for CK (Fig. 3.17 d-f). However, other tumor areas had a
low expression of CK. In the other mice, the majority of the tumor cells pre-
sented a low or moderate expression of CK, with some tumor areas negative
for CK (Fig. 3.17 j-l; m,n). The expression of CK was either cytoplasmic
or on the membrane of metastatic cells. Small tumor areas expressing CK
were found in some mice without visible lung metastases by IVIS (Fig. 3.17,
o).
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(a) (b)
(c) (d)
(e) (f)
Figure 3.12: Representative pictures of regional lymph node metastasis in
athymic nude male mice at different magnifications (40x, 100x, 400x): tumor
cells were located into the subcapsular sinus and extended into the cortex
11 weeks (a-c) and 6 weeks (d-f) after the injection (black arrows). In both
cases, metastatic cells had the same features of the primary tumor (cells
grouped in nests with prominent nucleoli, nuclear atypia).
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 3.13: Representative pictures of regional lymph node metastasis in
athymic nude female mice at 40x (a, d), 100x (b, g), 200x (e), and 400x
(c, f, h): tumor cells were located into the subcapsular sinus and in some
cases infiltrated into the cortex (arrows) (d-f). At a greater magnification,
metastatic cells could be recognized by nuclear atypia and prominent nucleoli
(c, f, h).
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 3.14: Representative pictures of lung metastasis in mice 510 (a-c),
508 (d-f), and 507-509 (g-h) at different magnifications (40x, 100x, 400x). In
the first mouse, whose lung metastases were also macroscopically observed,
tumor cells invaded the whole lung parenchyma. Cellular nests and areas of
keratinization with pyknotic nuclei were also present (a, b, arrows). In the
other mouse, metastatic nodules of different dimensions were present (d-e,
g-h). Tumor cells displayed nuclear atypia, prominent nuclei and assumed
various shapes (f), especially in mouse 510 (c). Interestingly, compact cel-
lular aggregations were observed in the mice in which lung metastases were
not detected by IVIS (g,h; 40x). At a greater magnification, these cells were
atypic.
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(a) (b)
(c) (d)
(e) (f)
(g)
Figure 3.15: Representative pictures of lung metastasis in female mice at
100x (a, c), 200x (e), and 400x (b, d, e, f, g). Metastatic nodules were
present within the lung parenchyma (a, c). At a greater magnification,
tumor cells displayed atypia (nuclear atypia, pleomorphism). As in the
male mice, cellular aggregations were present also in the lungs of the mice
which did not present lung metastases by IVIS (e-g). Indeed, some atypic
cells were observed in some areas of the lung.
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(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
(j) (k) (l)
(m) (n)
Figure 3.16: Representative pictures of H&E and IHC for cytokeratin (CK)
of the primary tumor (a-f) and lymph node metastases (g-n) in athymic
nude female and male mice at 40x, 100x and 400x. The tongue tumor was
positive for CK. Some groups of tumor cells had a high expression of CK
(d, e). CK-positive tumor cells were also located into the subcapsular sinus
and in the cortex of the regional lymph nodes (j-l). The expression of CK
was mostly on the membrane. Non-specific cytoplasmic staining of plasma
cells. Various degree of CK expression was also observed in the metastatic
cells (j-l, n).
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(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
(j) (k) (l)
(m) (n) (o)
Figure 3.17: Representative pictures of H&E and IHC for CK of lung metas-
tases in athymic nude female and male mice at 40x, 100x, and 400x. Tumor
areas displayed various degrees of CK expression: in the mouse 510, several
cells were strongly positive for CK, while a low or absent expression of CK
was observed in other tumor areas. In the other mice, most of the tumor
cells in the lungs presented a low-moderate expression of CK, with some tu-
mor areas negative for CK. At a greater magnification, these cells displayed
a marked atypia (f, l, n). A few areas positive for CK were also found in
some mice, in which lung metastases were not observed by IVIS (o, 200x).
Non-specific staining of plasma in blood vessels was present.
Chapter 4
Development of a model of
OSCC lung metastasis
4.1 Materials and Methods
Generation of the HSC-3 GFP/Luc M1 cell line All animal exper-
iments were approved by the IACUC at the Houston Methodist Research
Institute in accordance to the National Institutes of Health Guide for the
Care and Use of Laboratory Animals.
Five athymic nude-Foxn1nu mice (Envigo), male, 5-6 weeks old, weight
24.84 ± 2.15, were injected with 1 x 105 HSC-3 GFP/Luc cells in 100 µl
of PBS into the tail vein (day 0). IVIS Spectrum In-Vivo Imaging System
(Perkin Elmer Inc., Waltham, MA) was performed weekly to monitor the
growth of lung metastases following the same procedure reported in the
Material and Methods of Chapter 3.
Thirty-four days after the injection, one mouse with large lung metas-
tases was sacrificed. Both lungs were removed and were minced into small
pieces with scissors and scalpel. The minced tissue underwent enzymatic
dissociation using collagenase IV at a concentration of 0.7 mg\ml in D-PBS
and incubated at 37◦C for 50-60 minutes. The digestion product was then
filtered using a 70 µm cell strainer (Fisherbrand TM) and plated in a 10 cm
Petri dish in DMEM 10 % FBS plus 2 % of PS for the first 3 days. The cells
were then expanded in vitro in media 10% FBS plus 1% of PS .
After a few passages, the cells were sorted for GFP expression as described
in the Material and Methods of Chapter 3 to select only the human tumor
cells. After sorting, pure HSC-3 GFP/Luc M1 cells were obtained and were
allowed to grow in the normal media. The Luc expression of HSC3 GFP/Luc
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M1 cells was then confirmed by IVIS, using the same procedure described
in the Material and Methods of Chapter 3.
Development of a model of OSCC lung metastasis with HSC-3
GFP/Luc M1 cells To evaluate the in vivo metastatic potential of HSC-
3 GFP/Luc M1 cells, 5 athymic nude Foxn1nu mice (Envigo), female, 7-8
weeks old, weight 21.22 ± 0.70, were injected with 0.5 x 106 cells in 100
µl of PBS into the tail vein. The growth of lung metastases was monitored
periodically by IVIS. All mice were humanely sacrificed through an overdose
of isoflurane and cervical dislocation 46 days after the injection.
Ex vivo IVIS of the lungs, heart, liver, and spleen was then performed.
The organs were fixed in Bouin′s solution (lungs) or in 10% buffered formalin
solution (all other tissues) and embedded in paraffin as reported in the
Material and Methods of Chapter 3. The presence of lung metastases was
further confirmed by H&E staining. Pictures were taken using an upright
microscope system (Nikon Eclipse 80i).
4.2 Results
The aim of the present study was to establish a lung metastasis model of
OSCC by injection into the tail vein. Despite the limitations of this model,
it is widely used to reproduce lung metastases of different type of cancers.
In addition, it has been reported that lung metastases established through
the tail vein injection of tumor cells may be similar to those obtained in or-
thotopic models[54]. In addition, several authors have reported an increased
metastatic potential and a different gene expression between parental tumor
cell lines and the same tumor cells isolated from metastases. These findings
were reported regarding OSCC cells isolated from lymph node metastases by
Masood et al.[49]. In addition, a few articles have been published on lung
metastases of OSCC. For these reasons, a model of OSCC lung metasta-
sis was established using HSC-3 cells isolated from lung metastases (HSC-3
GFP/Luc M1). In this new model, lung metastases were first observed 21
days after injection. Forty-six days after the injection, all five mice were sac-
rificed and the presence of lung metastases was evaluated by ex vivo IVIS
and histology. The lung metastasis prevalence of this model was 60% (3\5)
by ex vivo IVIS. The histological analysis confirmed the presence of the lung
metastases and revealed compact cellular aggregations also in the lungs of
the remaining 2 mice.
4.2.1 Isolation of HSC-3 GFP M1 cell line and cell sorting
One male mouse injected with 1 x 105 HSC-3 GFP/Luc cells started to
develop lung metastases two weeks after the injection (Fig. 4.1 a). Lung
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metastases continued to grow, developing a moderate bioluminescent signal
29 days after the injection. Thirty-four days after the injection, the mouse
was sacrificed and the lungs with visible tumor masses were collected (Fig.
4.1 b, 1). At cell sorting, the cells isolated from the lungs had a good
expression of GFP (FITC intensity between 104 and 105) and Luc (Fig. 4.1
b, 2, 3).
4.2.2 New model of lung metastasis with HSC-3 M1 GFP/Luc
cell line
Evaluation of the lung metastases by IVIS
In this model, the development of lung metastases was not homogeneous
among all the animals injected. Indeed, the first presence of lung metastases
was observed 22 days after the injection in one mouse (Fig. 4.2 a, b). Two
weeks later, two more mice presented large lung metastases, while no signal
was observed in the remaining two mice (Fig. 4.2 c). All the mice were
then sacrificed 46 days after the injection and ex vivo IVIS of the lungs,
liver, and spleen was performed. Large lung metastases were detected in
both lungs and the left lobe was more involved in two mice (Fig. 4.3) In the
other mouse, the lung metastases occurred mainly in the right lobes. No
lung abnormalities were observed in the remaining two mice.
Histology
Representative pictures of the H&E of the lungs are reported in Fig. 4.4.
In the mice, in which lung metastases were already visible by IVIS, several
coalescent metastatic nodules, which invaded a large section of the lungs
were present. The cell density of the metastases was high, except for few
areas where the cells seemed to be more scattered (a, b). The cell archi-
tecture consisted of nests with little (e) or abundant stroma (b, h). Few
areas also presented keratinization (a, e, h, i). At a greater magnification,
metastatic cells appeared pleomorphic, assuming a round, ovoid and spindle
morphology. Other features of these cells included a prominent nucleolus, a
marked anysokariosis, anysoanisocytosiscytosis, and nuclear atypia (f, i).
The histological analysis of the lungs of the remaining two mice revealed
the presence of cellular aggregations in few areas (j-l). Such structures con-
sisted of cells with a high variability in the nuclear size and shape and a
prominent nucleolus. Therefore, they were identified as lung micrometas-
tases. These histological findings also in the mice in which lung metastases
were not previously detected by ex vivo IVIS revealed a high aggressivity of
this new model of lung metastasis.
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(a)
(b)
Figure 4.1: (a) IVIS for lung metastases: the mouse from which HSC-3
GFP M1 cell line was isolated developed already lung metastases from day
15. (b) 1. Pictures of the lungs at necropsy: macroscopic whitish tumor
masses (arrows) 2. IVIS of HSC-3 GFP M1: initial concentration 0.5 x 106
cells/100µl. DMEM served as negative control. 3. Sorting of HSC-3 M1
cell line by GFP expression: positivity for GFP found in 17.4% of cells (BD
FACSAria II Cell Sorter).
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(a)
(b)
(c)
Figure 4.2: IVIS for lung metastases of the athymic nude mice faced on the
back (a) and on the front (b): the first signal of moderate intensity from the
lungs (106) was observed three weeks after the injection. (c) Five weeks after
the injection, the signal was very intense in 3\5 mice (108), which developed
large lung metastases.
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Figure 4.3: IVIS of the mice faced on the back and front 46 days after the
injection (right). Ex vivo IVIS of the lung (L), liver (LV), and spleen (S) of
all 5 mice (left). Large lung metastases were observed in 3/5 mice. No liver
metastases were detected.
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(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
(j) (k) (l)
Figure 4.4: Representative pictures of lung metastases in the model with
HSC3 GFP/Luc M1 at 40x, 100x, and 400x. (a)-(i): histology of the lung
metastases already detected by ex vivo IVIS. A diffuse tumor cell infiltration
was observed, with cell islands and keratinization areas. At a greater mag-
nification, cell nuclei were different in size and shape (i, f). (j)-(l): histology
of the lungs of the remaining two mice, in which micrometastases were ob-
served. At a greater magnification, the tumor cells assumed a round to
spindle morphology and had large nuclei with prominent/multiple nucleoli
(l).
Chapter 5
Use of pDox on a new OSCC
metastatic cell line
5.1 Materials and Methods
Cell line For the present experiment, the cell line HSC-3 GFP/Luc M1
was used. The procedure of cell isolation and the culture method are re-
ported in the Material and Methods of Chapter 4.
Synthesis and preparation of pDox nanoparticles The procedures
used to synthesize pDox and to form NPs are reported in the Material and
Methods of Chapter 2.
MTS Assay HSC-3 GFP/Luc M1 cells were plated in a 96-well plate (3.5
x 103 cells per well) and incubated for 24 h to allow cell adhesion. After
that, the cells were treated with different concentrations of doxorubicin and
equimolar amounts of pDox NPs. After 72 and 96 h, cells viability was
evaluated through MTS assay (Promega) according to the manufacturer′s
protocol.
Uptake studies of pDox nanoparticles and free doxorubicin HSC-3
GFP/Luc M1 cells (2 x 104 cells per chamber) were seeded on 4-well chamber
slides (BD Falcon) and incubated for 24 h. Cells were then treated with 5
µM of free doxorubicin and equimolar amounts of pDox NPs for 6 h and
24 h. When the endpoint was reached, cells were fixed and stained using
the same procedure and reagents reported in the Material and Methods of
Chapter 2. Z-stack images were then captured using a confocal microscope
(Nikon A1 Confocal Imaging system) using the same method reported in
the Material and Methods of Chapter 2.
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Statistical analysis Statistical analyses were performed using one-way
analysis of variance (ANOVA) with the GraphPad Prism software. Differ-
ences at p < 0.05 were considered to be statistically significant.
5.2 Results
After the isolation of the OSCC cell line HSC-3 GFP/Luc M1 and the de-
velopment of a highly aggressive lung metastatic model in vivo, these cells
were treated with the free form of doxorubicin and pDox NPs. The aim of
the viability assay and the qualitative uptake study was to collect prelimi-
nary data on the response of the new cell line to these treatments. Indeed,
some articles have been published, reporting a difference between parental
tumor cells and tumor cells isolated from the metastases. In OSCC, lit-
tle is known about lung metastases and the possible effective therapeutic
strategies to adopt. Interestingly, the viability assay after 72 and 96 h of
treatment with pDox NPs and doxorubicin and the cellular uptake study
conducted on HSC-3 GFP/Luc M1 did not show different results from the
ones reported for HSC-3 cells (see 2.2.1).
5.2.1 Viability assay for HSC-3 GFP/Luc M1 cells after treat-
ment with doxorubicin and pDox NPs
Results obtained from MTS assay of HSC-3 GFP/Luc M1 cells treated with
different concentrations of the free form of doxorubicin and the pDox NPs
are summarized in Fig. 5.1. The treatment with high concentrations of the
free form of doxorubicin (0.5 and 1 µM) resulted in a significantly lower
cell viability than controls at both time points. However, there was no
statistically significant difference between the cell treatment with 0.5 and 1
µM of doxorubicin. In addition, the cells treated for 96 hours had a lower
viability than those of cells treated for 72 hours.
The measurements of the size of pDox NPs were performed using intensity
average. The average size of pDox NPs was 129.1 ± 9.214 nm. After 72 h
of treatment, no significant effect of pDox NPs on the cell viability was
observed, while the treatment with 0.5 and 1 µM pDox NPs resulted in a
significant cytotoxic effect after 96 h of treatment (Fig. 5.1 a, b).
Additionally, doxorubicin exerted significantly more cytotoxic effect than
pDox NPs at 72 (a) and 96 h (b) in this metastatic cell line of OSCC.
However, the difference between the treatment with the highest dosage of
the free form of doxorubicin and pDox NPs was statistically significant after
72 h (P=0.028), but not after 96 h (P=0.189). This finding proved that
both doxorubicin and pDox NPs may be effective in killing the metastatic
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HSC-3 GFP/Luc M1 cell line, as well as the parental cells HSC-3 (see 2.2.1).
No statistically significant difference was observed between the viability of
the two cell lines treated with doxorubicin or pDox NPs.
5.2.2 Cellular uptake study of pDox NPs and free doxoru-
bicin in HSC-3 GFP/Luc M1 cells
Fig. 5.2 reported the qualitative cellular uptake performed on HSC-3 GFP/Luc
M1 after 6 and 24 h of treatment with pDox NPs and doxorubicin. After 6
h of treatment, doxorubicin was visible only within the nucleus of the cells
treated for 24 h with pDox NPs. In contrast, doxorubicin was present in
the cells treated with the free form after 6 and 24 h of treatment. This find-
ing confirmed the delayed entry of pDox NPs which also occurred in HSC-3
GFP/Luc M1 cell line.
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(a)
(b)
Figure 5.1: Viability assay results for HSC-3 M1 cell line after 72 (a) and 96 h
(b) of treatment with different concentrations of pDox NPs and doxorubicin.
Data are expressed as the mean ± SEM of three experiments. ∗P ≤ 0.05,
∗∗ P ≤0.01 by one-way ANOVA statistical analysis and the post hoc Tukey
test.
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(a)
(b)
Figure 5.2: Z-stack confocal images after 6 (a) and 24 h (b) of treatment with
doxorubicin and pDox NPs. DAPI (blue fluorescence) was used to stain the
nuclei. Green fluorescence represents the cytoskeleton. Propidium iodide
channel (red fluorescence) was used to detect doxorubicin in the free and
polymeric form. The pink/purple fluorescence indicates a co-localization of
PI and DAPI. This occurred in few cells after 24 h of treatment with pDox
NPs. Scale bar represents 10 µm.
Chapter 6
Discussion and Conclusion
6.1 pDox NPs were significantly less cytotoxic than
free doxorubicin on HSC-3 and HSC-3 M1 cells
A cell viability assay and a qualitative cellular uptake study of doxorubicin
and pDox were performed on two cell lines: HSC-3 cells, which derives from
a human metastatic tongue SCC and HSC-3 M1 cells, which were isolated
from lung metastases developed in a mouse injected IV with HSC-3 cells. In
both cell lines, doxorubicin was significantly more cytotoxic than pDox NPs.
This may be owed to the fact that the cellular uptake of pDox was delayed
compared to the free form of doxorubicin. Indeed, the co-localization of
doxorubicin (PI) and DAPI occurred at later time points in the pDox NPs
group than the free doxorubicin group (after 6 h in HSC-3 and after 24 h
in HSC3 M1). The results obtained are in agreement with those obtained
on the same compounds by Xu et al.[66]. For this study, the human triple-
negative breast cancer cell lines MDA-MB-231 and MDA-MB-468 were used
and doxorubicin was more cytotoxic than pDox at a concentration≤ 1000
nM after 96 hours of treatment. In addition, the cellular entry of pDox
was delayed also in the MDA-MB-231 cell line compared with the free form
of doxorubicin[66]. Indeed, pDox co-localization with lysotracker reached a
high level only 8 hours after the treatment.
In addition, other studies reported more cytotoxicity with doxorubicin or
other drugs than with NPs encapsulating them[86, 106, 107]. Endo et al.[86]
observed a 14-fold more potent cytotoxic effect of free cisplatin compared to
30 nm-sized-polymeric micelles loaded with cisplatin in HNSCC cell lines.
Iafisco et al.[106] evaluated biomimetic apatite NPs loaded with doxorubicin
and a targeting moiety on a human gastric carcinoma cell line. In this
cell line, a minor toxicity and a slower cellular uptake of the NPs were
observed than the free doxorubicin. The same findings were reported in a
human breast cancer cell line treated with polymeric immuno-NPs loaded
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with doxorubicin. In this study, the NPs loaded with doxorubicin presented
also a slower nuclear transport inside the tumor cell than free doxorubicin,
in addition to a slower internalization rate[107].
The minor cytotoxicity and the slow uptake of pDox in OSCC cell lines
may represent the consequence of a slow intracellular transport and a slow
release of the drug, as reported by other authors[86, 106, 107]. In addition,
cell-type dependent differences may affect the cellular uptake of NPs. In a
study by Poller et al.[108], the uptake and toxicity of iron oxide NPs in four
breast cancer cell lines were influenced not only by the intrinsic properties of
NPs but also by the cell type, which may exhibit a difference in the activity
of the endocytic pathways[108]. To confirm this finding, further analysis of
these pathways may be performed in our OSCC lines and the triple-negative
breast cancer cell lines.
In conclusion, these findings on the OSCC cell lines do not represent a
drawback of the compound, because it may be less toxic also in vivo, as
reported by Endo et al.[86] in further experiments. In addition, the efficacy
of pDox relies mostly on the targeting efficiency of iNPG[66]. The use of
the platform iNPG-pDox seems promising as an anti-metastatic therapy for
OSCC, also because pDox in vitro toxicity was not significantly different
between HSC-3 M1 cells and the parental HSC-3 cell line.
6.2 The orthotopic model of OSCC metastasis re-
ported a moderate prevalence of lung metas-
tases
After demonstrating a significant cytotoxic effect of pDox on HSC-3 cells, an
orthotopic model of metastatic tongue SCC was established using the same
cell line. Fifty thousands of tumor cells were injected in the tongue of male
and female athymic nude mice and the growth of the primary tumor and
lung metastases was then evaluated by IVIS. Through this method, lung
metastases were observed in one male mouse 30 days after the injection,
while female mice did not present any visible lung metastasis. After the
mice sacrifice, IVIS of the mice organs (tongue, mandibular lymph nodes,
lungs, spleen, liver) revealed the presence of the primary tumor in 100% of
male mice and 80% of female mice. Lymph node metastases were present in
80% and 67% in male and female mice respectively, while 60% of male mice
presented lung metastases. In contrast, only 22% of female mice developed
visible lung metastases by ex vivo IVIS. In addition, the histological evalua-
tion of the lungs revealed some CK+ areas in the remaining two male mice,
while cellular aggregations were observed also in the female mice, in which
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metastases were not visible by ex vivo IVIS.
Interestingly, our orthotopic model reported a moderate-high prevalence
of lung metastases. Other studies conducted with the same cell line did
not obtain our same results[44, 45]. In such studies, a high number of cells
(1.75-4x105) were injected in the tongue, in contrast with the minor number
of cells injected in our study (5x104). In addition, the mice were sacrificed
3 weeks after the implantation[44, 45], while, in our study, the first signal
of lung metastases was observed only 30 days after the injection. Therefore,
the injection of a high number of cells may result in a faster growth of
the primary tumor and the sacrifice of the animals before lung metastases
become evident[44, 45].
Only a few studies[32, 50, 52] reported lung metastases in ≥ 40% of the
mice. The orthotopic model of OSCC reported by Lou et al.[52] was a
syngeneic one, while our model was a xenograft. Bais et al.[32] injected
0.5x106 of UM-SCC-2, a cell line derived from a recurrent tumor (T2N0M0)
in the oral cavity. As stated in the 1.1.3, tumors with an aggressive behavior
are also at high risk of local recurrence and present histological indicators
of malignancy[7]. Finally, 83% of lung metastases were reported in an or-
thotopic model of OSCC with a human cell line isolated from lymph node
metastases of the mice (USC-HN3-GFP-G1)[50].
Interestingly, the same procedure repeated three times with HSC-3 cell
line did not result in an increase of the prevalence of lung metastases (10%
vs 10% of the parental cells), in contrast to the lymph node metastases (90%
vs 30% of the parental cells)[44]. Indeed, a different metastatic potential to
lymph nodes and lungs was reported between the OSCC cell lines[49, 55].
Despite the metastatic potential to lungs was evaluated only by IV injection
of OSCC cells, the study revealed a different gene expression between the
metastatic and non-metastatic cell lines[55]. In particular, high levels of AP-
1 family molecules such as c-Jun, FosL1 and JunB were found in metastatic
cells compared to non-metastatic ones. A high expression of these genes
and disruptive TP53 mutations were also observed in OSCC cell lines with
the highest regional metastatic potential compared to less metastatic OSCC
ones[49]. The presence of both lymph node and lung metastases in our study
may be indicators of the high metastatic potential of the HSC-3 cell line,
which deserves further investigation. In addition, these findings confirm
the correlation between regional and distant metastases (DMs) observed in
the clinical setting[23, 24]. However, the limitations of our study were the
use of only one cell line (HSC-3) and the lack of a gene expression analysis
of HSC-3 cells. To confirm and/or to discover novel genes involved in the
metastatic process, an in vitro and in vivo evaluation of the gene expression
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and the distant metastatic potential may be performed between HSC-3 cells
and other OSCC cell lines.
6.3 Male and female athymic nude mice presented
a different prevalence of lung metastases
Another interesting finding of the present study was the large difference
observed in the prevalence of lung metastases between male and female
mice. To date, our study is the first which established an orthotopic model
of OSCC lung metastasis in both sexes of mice. Indeed, only male[44, 48]
or female mice[32, 43, 45] were used in other studies. As stated in the
1.1.1, OSCC has a higher prevalence in men than in women, although this
difference is now less marked[3]. Interestingly, a higher prevalence of DMs in
men than in women was also reported by some clinical studies[26, 28, 109].
However, the sex of the patient was not reported as a significant indicator
of DMs and it may be probably due to the higher frequency of OSCC in
males than in females[28, 109, 110]. Nevertheless, further studies conducted
on both sexes of mice may be needed in order to confirm this difference in
the prevalence of OSCC lung metastases.
6.4 Lung metastases displayed similarities with the
metastases reported in HNSCC patients
Finally, the localization of lung metastases in preferentially one lung (ex-
cept for one male mouse, in which both lungs were involved) and the number
of macrometastases (1-2) seem to be similar to the findings observed in the
study by Osaki et al.[27]. In this study, the presence of DMs was evalu-
ated in 636 HNSCC patients and lung metastases were found in 35 patients.
One of the lungs was involved in the majority of the patients (right: 18\35;
left: 5\35 ), while only 8 patients presented an involvement of both right
and left lungs. In addition, 18 patients presented a single metastatic nod-
ule in the lungs, while a diffuse tumor infiltration was reported only in 3
patients[27]. The similarity between the lung metastases obtained in our
orthotopic model of OSCC and those reported in patients is encouraging.
However, a limit of our study was the use of a xenograft model. Indeed, the
nude mouse (nu/nu) lacks lymphocytes T, which are involved in the tumor
progression[29, 31]. Despite this difference, further characterization of the
mouse model and histological analyses of lung metastases from patients may
be necessary to prove the correspondence between our orthotopic model and
the OSCC in patients.
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6.5 Lung metastases in the IV model of HSC-3 M1
cells presented a diffuse tumor cell infiltration
In addition to the orthotopic model of OSCC metastasis, another mouse
model of OSCC lung metastasis was established through IV injection of
OSCC cells. In order to acquire more significant results, the cell line HSC-
3 M1 was used. This cell line was isolated from the lung metastases of a
mouse, which was previously IV injected with HSC-3 cells. In this model, the
lung prevalence was 60% (3\5) in female mice by ex vivo IVIS. In addition,
the histological analysis of the remaining two mice revealed the presence
of compact aggregations with atypic cells. To date, this is the first study
in which a mouse model of metastatic OSCC was established using OSCC
cells isolated from lung metastases. The prevalence of metastases observed
in our study is similar to those reported in the other studies[55, 92]. In-
deed, Hyakusoku reported a 90% of lung metastasis rate injecting 1x106 of
HSC-3 cells, while a 100% of lung metastasis rate was obtained injecting
2x106 CAL-27 cells[92]. However, a pan-CK staining of the lungs was not
performed to further confirm the metastatic nature of the cellular aggrega-
tions in the remaining 2 mice. In addition, the other studies assessed the
presence of lung metastases only at the study endpoint by histology and
pan-CK staining, while we used IVIS to track the growth of lung metastases
during the experiment and histology was performed at the sacrifice of the
animals. Indeed, in vivo imaging techniques have allowed researchers not
only to follow the development of single metastatic nodule but also to follow
the response of the therapy over time[29, 66]. The use of IVIS is emerging
also in OSCC research. Therefore, few studies used in vivo imaging[32, 47].
Finally, several coalescent metastatic nodules and a diffuse tumor cell in-
filtration occurred in our model and other reported models of OSCC lung
metastasis reported several metastatic nodules in the lungs[55, 92]. Accord-
ing to Osaki et al.[27], these findings were observed only in a few patients
(3-6\35). Therefore, this mouse model may not be the best option to test
future anti-metastatic therapies for OSCC.
6.6 Conclusions
Advanced-stage OSCC cases still present a 5-year survival rate of less than
50%, despite the multimodality therapy and the administration of molecular-
targeted agents. In clinical studies, nanomedicine drugs proved to be effec-
tive in the treatment of some type of cancers, although a significant efficacy
was not achieved against metastatic sites. Third-generation platforms and
more elaborated ones have been developed to target more efficiently sites of
metastases such as the lungs and liver. One of these platforms, iNPG-pDox
CHAPTER 6. DISCUSSION AND CONCLUSION 77
demonstrated to be effective against lung metastases in an orthotopic model
of breast cancer.
From the results reported in the present dissertation, it can be concluded
that pDox NPs were efficiently internalized and exerted their cytotoxic ac-
tion also on HSC-3 M1 cells. Therefore, further in vivo studies may be
necessary in order to evaluate the therapeutic efficacy of iNPG-pDox.
In vivo, lung metastases were successfully reproduced in two different
mouse models of OSCC, with a moderate-high prevalence of lung metastases
observed after the IV injection of HSC-3 M1 cells (non-orthotopic model)
and the tongue injection of HSC-3 cells (orthotopic model). Interestingly,
the lymph node and lung metastases obtained in the orthotopic model pre-
sented some features in common with the data reported on HNSCC patients.
For these reasons, future efficacy studies of anti-metastatic therapies such
as iNPG-pDox may offer a better contribution to clinical trials, if performed
using an orthotopic model of lung metastasis OSCC. Moreover, an ortho-
topic model of OSCC lung metastasis may be a useful tool to investigate
the mechanism of regional lymph node and lung metastases in OSCC.
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